<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Management of acute moderate and severe traumatic brain injury
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Management of acute moderate and severe traumatic brain injury
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Management of acute moderate and severe traumatic brain injury
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Venkatakrishna Rajajee, MBBS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael J Aminoff, MD, DSc
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Maria E Moreira, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alejandro A Rabinstein, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Janet L Wilterdink, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 09, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2557656976">
         <span class="h1">
          INTRODUCTION AND DEFINITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Traumatic brain injury (TBI) is a leading cause of death and disability. In 2013, there were approximately 2.5 million emergency department (ED) visits, 282,000 hospitalizations, and 56,000 deaths related to TBI in the United States [
         <a href="#rid1">
          1
         </a>
         ]. Many survivors live with significant disabilities, resulting in major socioeconomic burden as well. In 2010, the economic impact of TBI in the United States was estimated to be $76.5 billion in direct and indirect costs [
         <a href="#rid2">
          2,3
         </a>
         ]. More severe TBI carries a disproportionately greater economic toll.
        </p>
        <p>
         The severity of TBI is most commonly graded using the Glasgow Coma Scale (GCS), assessed following the initial resuscitation and within 48 hours of injury  (
         <a class="graphic graphic_table graphicRef81854" href="/z/d/graphic/81854.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ]. Severe TBI is defined by a GCS score &lt;9 [
         <a href="#rid5">
          5
         </a>
         ]. Previously, a GCS score of 9 through 12 was considered moderate injury and a GCS score of 13 through 15 was considered mild injury [
         <a href="#rid6">
          6
         </a>
         ]. More recently, however, the recognition that over one-third of patients with a GCS score of 13 have intracranial lesions has led to a reevaluation of this classification, with GCS scores 9 through 13 considered moderate injury and 14 through 15 considered mild [
         <a href="#rid7">
          7-10
         </a>
         ].
        </p>
        <p>
         One of the major advances over the past two decades in the care of patients with severe head injury has been the development of standardized approaches that follow international and national guidelines [
         <a href="#rid11">
          11-14
         </a>
         ]. The Brain Trauma Foundation (BTF) updated its guidelines for the management of severe TBI in 2016 [
         <a href="#rid15">
          15
         </a>
         ]. The intent of these guidelines has been to use existing evidence to provide recommendations for management in order to lessen heterogeneity and improve patient outcomes. Unfortunately, the lack of randomized clinical trials addressing many aspects of care of the severe TBI patient has meant that the strength of supporting data for several treatment concepts is relatively weak. Despite this, there is evidence that treatment in centers with neurosurgical support, especially in neurointensive care units that operate based on guideline-driven protocols, is associated with better patient outcomes [
         <a href="#rid16">
          16-23
         </a>
         ].
        </p>
        <p>
         Patients with moderate or severe head injury frequently have other traumatic injuries to internal organs, lungs, limbs, or the spinal cord. These are discussed in separate topic reviews. (See
         <a class="medical medical_review" href="/z/d/html/13854.html" rel="external">
          "Initial management of trauma in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113837.html" rel="external">
          "Initial management of moderate to severe hemorrhage in the adult trauma patient"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7956.html" rel="external">
          "Overview of inpatient management of the adult trauma patient"
         </a>
         .)
        </p>
        <p>
         This topic discusses the management of acute moderate and severe TBI. While most pertinent to severe TBI, the principles of management below are also relevant to moderate TBI (sometimes referred to as "potentially severe" TBI) [
         <a href="#rid7">
          7,8
         </a>
         ]. The epidemiology and pathophysiology of TBI, the management of mild TBI, acute spinal cord injury, and other aspects of care of the trauma patient are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4825.html" rel="external">
          "Traumatic brain injury: Epidemiology, classification, and pathophysiology"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4828.html" rel="external">
          "Acute mild traumatic brain injury (concussion) in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4819.html" rel="external">
          "Acute traumatic spinal cord injury"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/344.html" rel="external">
          "Skull fractures in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          INITIAL EVALUATION AND TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Prehospital
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary goal of prehospital management for moderate and severe TBI is the prevention and treatment of hypotension and hypoxia, two systemic insults known to be major causes of secondary injury after TBI [
         <a href="#rid24">
          24-29
         </a>
         ]. The injured brain is especially vulnerable to secondary insults in the first 24 hours. In a meta-analysis of clinical trials and population-based studies, hypoxia (PaO
         <sub>
          2
         </sub>
         &lt;60 mmHg) and hypotension (systolic blood pressure [BP] &lt;90 mmHg) were present in 50 and 30 percent of patients, respectively, and were each associated with a higher likelihood of a poor outcome: hypoxia (odds ratio [OR] 2.14); hypotension (OR 2.67) [
         <a href="#rid25">
          25
         </a>
         ]. Even low-normal BP may be associated with poor outcomes. An analysis of 5057 patients with TBI entered into a European trauma registry revealed that the odds of death tripled with an admission systolic BP &lt;90 mmHg, doubled with a systolic BP &lt;100 mmHg, and were 1.5 times greater with an admission systolic BP &lt;120 mmHg, after controlling for potential confounders [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         Changes in prehospital management that aim to normalize oxygenation and BP may be associated with improved outcomes [
         <a href="#rid31">
          31-35
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prehospital airway management
         </strong>
         – Prehospital endotracheal intubation is recommended in patients with TBI and a Glasgow Coma Scale (GCS) score &lt;9, an inability to protect their airway, or an SpO
         <sub>
          2
         </sub>
         &lt;90 percent despite the administration of supplemental oxygen [
         <a href="#rid36">
          36
         </a>
         ]. Patients who are not intubated should receive supplemental oxygen as necessary to maintain an SpO
         <sub>
          2
         </sub>
         &gt;90 to 93 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When intubation is indicated but adequate expertise is unavailable, or an attempt at intubation is unsuccessful, bag-mask ventilation should be performed in conjunction with basic airway-opening maneuvers or airway adjuncts.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The benefit of prehospital intubation is uncertain, with studies finding conflicting results [
         <a href="#rid37">
          37
         </a>
         ]. Large observational studies have not found a benefit [
         <a href="#rid38">
          38
         </a>
         ] and in some cases found harm to be associated with prehospital intubation [
         <a href="#rid39">
          39
         </a>
         ]. One analysis suggested that prehospital intubation performed by aeromedical crews (often more experienced in the management of critically ill patients than ground crews) was associated with better outcomes [
         <a href="#rid40">
          40
         </a>
         ]. In a randomized trial of 312 patients with severe TBI transported by ground in Australia, prehospital rapid-sequence intubation by paramedics was associated with better functional outcome at six months compared with intubation in hospital (51 versus 39 percent of patients with favorable outcome on the extended Glasgow Outcome Scale [E-GOS]) [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Thus, the following factors should be considered by emergency medical service (EMS) systems when developing protocols that address the use of prehospital intubation in patients with severe TBI [
         <a href="#rid38">
          38
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Appropriate hands-on training of prehospital providers in rapid-sequence intubation, along with ongoing maintenance of skills, is essential.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Both hypoventilation and hyperventilation should be avoided following intubation. Quantitative capnography may be useful in this situation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hemodynamic instability may occur following rapid-sequence intubation, and immediate measures should be taken to correct hypotension prior to emergency department (ED) arrival.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         While patients with more severe injury and a lower GCS score are more likely to require intubation, the GCS should not be the sole factor in making decisions on prehospital intubation. Patients with a poor initial neurologic exam will often improve prior to ED arrival.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Factors that may influence the decision to intubate by a trained provider include:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Low GCS
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Poor chest rise despite the use of airway repositioning and basic adjuncts (oropharyngeal airway device, nasopharyngeal airway device, suctioning)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         SpO
         <sub>
          2
         </sub>
         &lt;90 to 93 percent despite the use of supplemental oxygen
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Clinical signs of cerebral herniation (see
         <a class="local">
          'Patients with impending cerebral herniation'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Evidence of aspiration
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Long transport time
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The use of a supraglottic airway device may be lifesaving when intubation is indicated but cannot be performed. (See
         <a class="medical medical_review" href="/z/d/html/106475.html" rel="external">
          "Extraglottic devices for emergency airway management in adults", section on 'Supraglottic airways'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blood pressure management
         </strong>
         – Prevention of hypotension in the prehospital setting is best accomplished by adequate fluid resuscitation using isotonic crystalloids. While hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         has theoretical benefits, including the need for a lower volume to achieve intravascular filling in patients with ongoing blood loss, randomized controlled trials in the prehospital setting have not suggested benefit [
         <a href="#rid42">
          42,43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurologic assessment
         </strong>
         – Patients with TBI should be assumed to have a spinal fracture and appropriate precautions taken to stabilize and immobilize the spine during transport. (See
         <a class="medical medical_review" href="/z/d/html/4819.html" rel="external">
          "Acute traumatic spinal cord injury"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A prehospital assessment of the GCS can be helpful for early triage decisions  (
         <a class="graphic graphic_table graphicRef81854" href="/z/d/graphic/81854.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prehospital antifibrinolytic therapy
         </strong>
         – We do not recommend the prehospital administration of antifibrinolytic therapy. In a randomized trial of 966 patients with TBI and GCS score ≤12, prehospital administration of
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         within two hours of injury did not improve mortality or six-month neurologic outcome [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Emergency department
         </span>
        </p>
        <p class="headingAnchor" id="H1254475718">
         <span class="h3">
          Assessment and initial support
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the early hospital admission phase of patients with moderate or severe head injury, treatment and diagnostic assessment are performed according to the Advanced Trauma Life Support (ATLS) protocol. Important considerations specific to TBI include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endotracheal intubation should be performed at this time for all patients with a GCS score &lt;9, inability to protect the airway, inability to maintain SpO
         <sub>
          2
         </sub>
         &gt;90 percent despite the use of supplemental oxygen, or clinical signs of cerebral herniation. Adequate oxygenation (PaO
         <sub>
          2
         </sub>
         &gt;60 mmHg) continues to be a priority. Specific aspects of this procedure in this setting are described separately. (See
         <a class="medical medical_review" href="/z/d/html/266.html" rel="external">
          "Airway management in the patient with elevated ICP for emergency medicine and critical care"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vital signs including heart rate, BP, respiratory status (pulse oximetry, capnography), and temperature require ongoing monitoring. Hypoxia, hypoventilation, hyperventilation, and hypotension are scrupulously avoided [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The patient should be assessed for other systemic trauma, per the ATLS algorithm. (See
         <a class="medical medical_review" href="/z/d/html/13854.html" rel="external">
          "Initial management of trauma in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A neurologic examination should be completed as soon as possible to determine the clinical severity of the TBI. The GCS is commonly used to assess and communicate neurologic status in this setting  (
         <a class="graphic graphic_table graphicRef81854" href="/z/d/graphic/81854.html" rel="external">
          table 1
         </a>
         ). The pupillary examination is crucial in the patient with TBI.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The Full Outline of UnResponsiveness (FOUR) score is an alternative scale for the assessment of patients with TBI  (
         <a class="graphic graphic_table graphicRef62673" href="/z/d/graphic/62673.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid45">
          45
         </a>
         ]. Potential advantages over the GCS include the ability to grade injury in intubated patients and to assess brainstem function. Prospective comparisons with the GCS in TBI have suggested an equivalent ability to predict long-term outcomes [
         <a href="#rid46">
          46,47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Neurologic status should be frequently assessed. Deterioration is common in the initial hours after the injury. Interruption of sedative infusions may be required to obtain an examination that best reflects the actual neurologic status of the patient.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation and management of increased intracranial pressure (ICP) should begin in the ED. Immediate lifesaving measures must be instituted in patients demonstrating clinical signs of impending or ongoing cerebral herniation [
         <a href="#rid48">
          48
         </a>
         ]. These signs include significant pupillary asymmetry, unilateral or bilateral fixed and dilated pupils, decorticate or decerebrate posturing, respiratory depression, and the "Cushing triad" of hypertension, bradycardia, and irregular respiration. Patients who fulfill criteria may undergo placement of an ICP monitor in the ED. (See
         <a class="local">
          'Initial (baseline) treatment'
         </a>
         below and
         <a class="local">
          'Patients with impending cerebral herniation'
         </a>
         below and
         <a class="local">
          'ICP and CPP monitoring'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A complete blood count, electrolytes, glucose, coagulation parameters, blood alcohol level, and urine toxicology should be checked. Efforts to reverse a coagulopathy should begin immediately. (See
         <a class="local">
          'Management of coagulopathy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Patients with TBI should be transferred to a hospital with neurosurgical services as soon as they are hemodynamically stable [
         <a href="#rid16">
          16-20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1947261538">
         <span class="h3">
          Antifibrinolytic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend immediate administration of the antifibrinolytic
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         to patients who present to hospital with moderate TBI (GCS greater than 8 and less than 13) within three hours of injury. Treatment appears to be safe and is associated with decreased mortality.
        </p>
        <p>
         Administration of
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         in the ED to other patients with TBI may also be reasonable. Examples include those with severe TBI but with bilateral reactive pupils, and patients with mild TBI (GCS &gt;12) and evidence of intracranial bleeding. However, a benefit is uncertain in these patients.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          Tranexamic acid
         </a>
         1 g is infused over 10 minutes, followed by an intravenous (IV) infusion of 1 g over eight hours.
        </p>
        <p>
         A benefit for
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         in patients with moderate TBI was demonstrated in the CRASH-3 trial that randomized 9202 TBI patients with GCS score &lt;13 or any evidence of intracranial bleeding on computed tomography (CT) scan within three hours of injury to tranexamic acid or placebo [
         <a href="#rid49">
          49
         </a>
         ]. Overall, the risk of head injury-related death was nonsignificantly lower in the tranexamic acid group (18.5 versus 19.8 percent, relative risk (RR) 0.94, 95% CI 0.86-1.02); this difference was statistically significant when patients with unreactive pupils (bi- or unilateral) were excluded (11.5 versus 13.2 percent, RR 0.87, 95% CI 0.77-0.98). Among patients with mild to moderate TBI, death was significantly reduced (5.8 versus 7.5 percent, RR 0.78, 95% CI 0.64-0.95), but not in patients with severe TBI (RR 0.99, 95% CI 0.91-1.07). The benefit of tranexamic acid was highly time dependent in patients with mild to moderate injury, but not in patients with severe injury. Vaso-occlusive events were not increased in patients who received tranexamic acid (1.5 versus 1.3 percent). Other smaller clinical trials have demonstrated the safety of tranexamic acid in TBI but individually did not demonstrate a benefit [
         <a href="#rid50">
          50-52
         </a>
         ]. A meta-analysis of these data along with CRASH-3 does suggest a modest mortality benefit in TBI and supports our recommendation for tranexamic acid within three hours of injury in patients with moderate TBI. While benefit may also be present in patients with severe TBI and bilateral reactive pupils, as well as in those with mild injury and evidence of intracranial bleeding on CT, the impact on mortality is uncertain in these groups.
        </p>
        <p>
         Mechanisms underlying the coagulopathy associated with trauma and the role of
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         in other acute traumatic injuries are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15147.html" rel="external">
          "Etiology and diagnosis of coagulopathy in trauma patients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Neuroimaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         CT is the preferred imaging modality in the acute phase of head trauma and should be performed as quickly as possible in patients with moderate as well as severe TBI, as certain lesions will indicate potentially lifesaving neurosurgical interventions. (See
         <a class="local">
          'Surgical treatment'
         </a>
         below.)
        </p>
        <p>
         A noncontrast CT scan will detect skull fractures, intracranial hematomas, and cerebral edema  (
         <a class="graphic graphic_diagnosticimage graphicRef68102 graphicRef67573 graphicRef53951 graphicRef56200" href="/z/d/graphic/68102.html" rel="external">
          image 1A-D
         </a>
         ). As these occur in patients with both moderate and severe TBI, guidelines recommend urgent head CT in all TBI patients with a GCS score of 14 or lower  (
         <a class="graphic graphic_table graphicRef81854" href="/z/d/graphic/81854.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Follow-up CT scanning should be performed if there is any clinical deterioration. (See
         <a class="local">
          'Neurologic monitoring'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2753925917">
         <span class="h3">
          Screening for blunt cerebrovascular injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         Injury to the carotid and vertebral arteries most commonly occurs as a result of skull base or vertebral fractures that involve vulnerable segments of these vessels. While blunt cerebrovascular injury (BCVI) may result in stroke at the time of injury, a latency of several hours to several days between the trauma and cerebrovascular event is common. Because antithrombotic therapy during this latent period may prevent subsequent ischemic strokes, BCVI is important to identify.
        </p>
        <p>
         We use the expanded Denver criteria to identify patients at high risk for BCVI, and perform multislice CT angiography of the head and neck to screen for such injury  (
         <a class="graphic graphic_algorithm graphicRef78174" href="/z/d/graphic/78174.html" rel="external">
          algorithm 1
         </a>
         ). In patients with moderate or severe TBI who have BCVI, we typically initiate
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         81 mg daily when such injury is discovered and if no contraindications exist; anticoagulation with heparin is typically contraindicated in the setting of acute moderate or severe TBI. Other aspects of treatment and monitoring of carotid or vertebral artery injury with or without ischemic stroke are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15154.html" rel="external">
          "Blunt cerebrovascular injury: Mechanisms, screening, and diagnostic evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16136.html" rel="external">
          "Blunt cerebrovascular injury: Treatment and outcomes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          SURGICAL TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Indications for emergency surgery after moderate or severe head injury are based upon neurologic status, usually defined by the Glasgow Coma Scale (GCS)  (
         <a class="graphic graphic_table graphicRef81854" href="/z/d/graphic/81854.html" rel="external">
          table 1
         </a>
         ), and findings on head CT criteria such as large hematoma volume or thickness and evidence of mass effect including midline shift  (
         <a class="graphic graphic_diagnosticimage graphicRef68102" href="/z/d/graphic/68102.html" rel="external">
          image 1A
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidural hematoma
         </strong>
         – Surgical guidelines recommend evacuation of an epidural hematoma (EDH)  (
         <a class="graphic graphic_diagnosticimage graphicRef56200" href="/z/d/graphic/56200.html" rel="external">
          image 1D
         </a>
         ) larger than 30 mL in volume regardless of a patient's GCS score; emergency surgical evacuation is recommended for patients with acute EDH and coma (GCS score ≤8) who have pupillary abnormalities (anisocoria) [
         <a href="#rid53">
          53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1107.html" rel="external">
          "Intracranial epidural hematoma in adults", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subdural hematoma
         </strong>
         – Acute subdural hematomas (SDHs) &gt;10 mm in thickness or associated with midline shift &gt;5 mm on CT should be surgically evacuated, regardless of the patient's GCS score  (
         <a class="graphic graphic_diagnosticimage graphicRef68102" href="/z/d/graphic/68102.html" rel="external">
          image 1A
         </a>
         ) [
         <a href="#rid54">
          54
         </a>
         ]. In addition, surgery is recommended for patients with a GCS score ≤8 if the GCS score has decreased by ≥2 points from the time of injury to hospital admission, and/or if the patient presented with asymmetric or fixed and dilated pupils, and/or if intracranial pressure (ICP) measurements are consistently &gt;20 mmHg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intracerebral hemorrhage
         </strong>
         – Surgical evacuation of a traumatic intracerebral hemorrhage (ICH) in the posterior fossa is recommended when there is evidence of significant mass effect (brainstem compression, obliteration of the fourth ventricle, effacement of the basal cisterns, or obstructive hydrocephalus) [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For traumatic ICH involving the cerebral hemispheres  (
         <a class="graphic graphic_diagnosticimage graphicRef53951" href="/z/d/graphic/53951.html" rel="external">
          image 1C
         </a>
         ), surgical indications are not as clearly defined. Consensus surgical guidelines recommend craniotomy with evacuation if the hemorrhage exceeds 50
         <sup>
         </sup>
         cm
         <sup>
          3
         </sup>
         in volume, or if the GCS score is 6 to 8 in a patient with a frontal or temporal hemorrhage greater than 20
         <sup>
         </sup>
         cm
         <sup>
          3
         </sup>
         with midline shift of at least 5 mm and/or cisternal compression on CT scan [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Penetrating injury
         </strong>
         – Superficial debridement and dural closure to prevent cerebrospinal fluid (CSF) leak is generally recommended [
         <a href="#rid57">
          57
         </a>
         ]. Small entry wounds can be treated with simple closure. Aggressive debridement and removal of deep foreign bodies such as bone or bullet fragments have not been shown to be effective in preventing delayed infection. The use of prophylactic broad-spectrum antibiotics is routine in this setting and is believed to have contributed to the reduced incidence of infection [
         <a href="#rid58">
          58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/344.html" rel="external">
          "Skull fractures in adults", section on 'Penetrating injuries'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Depressed skull fracture
         </strong>
         – Elevation and debridement are recommended for open skull fractures depressed greater than the thickness of the cranium or if there is dural penetration, significant intracranial hematoma, frontal sinus involvement, cosmetic deformity, wound infection or contamination, or pneumocephalus [
         <a href="#rid59">
          59
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/344.html" rel="external">
          "Skull fractures in adults", section on 'Depressed fractures'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6563.html" rel="external">
          "Skull fractures in children: Clinical manifestations, diagnosis, and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Refractory intracranial hypertension
         </strong>
         – Decompressive craniectomy may be lifesaving in patients with refractory elevations of ICP. (See
         <a class="local">
          'Decompressive craniectomy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          INTENSIVE CARE MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         A principal focus of critical care management for moderate or severe TBI is to limit secondary brain injury. In general, treatment efforts are aimed at intracranial pressure (ICP) management and maintenance of cerebral perfusion, as well as optimizing oxygenation and blood pressure (BP) and managing temperature, glucose, seizures, and other potential secondary brain insults.
        </p>
        <p>
         Other aspects of the general medical care of the trauma patient are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7956.html" rel="external">
          "Overview of inpatient management of the adult trauma patient"
         </a>
         .)
        </p>
        <p>
         Other extracranial traumatic injuries are managed simultaneously. (See appropriate topic reviews.)
        </p>
        <p class="headingAnchor" id="H4278881320">
         <span class="h2">
          Neurologic monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         A focus of management in moderate to severe TBI is the early recognition of neurologic worsening and the prevention of secondary brain injury. Of great concern, particularly in patients with moderate TBI, is neurologic worsening associated with expansion of hematoma or worsening cerebral edema, sometimes referred to as the "talk and die" phenomenon [
         <a href="#rid60">
          60,61
         </a>
         ]. While the exact frequency of this phenomenon in moderate TBI is uncertain, a rule of thumb described by some authors is that approximately 30 percent of patients with moderate TBI will develop neurologic worsening and expansion of mass lesions [
         <a href="#rid7">
          7,8
         </a>
         ].
        </p>
        <p>
         Serial neurologic examinations performed every 1 to 2 hours for at least 24 to 48 hours is critical in patients with moderate TBI since ICP monitoring is not typically performed in this population. (See
         <a class="local">
          'ICP and CPP monitoring'
         </a>
         below.)
        </p>
        <p>
         Urgent repeat imaging should be performed for any neurologic worsening. Evolution of CT findings is common and may indicate an alternative treatment approach in a significant number of patients [
         <a href="#rid62">
          62-66
         </a>
         ]. While there is no clear indication for routine follow-up CT scans in the absence of clinical change or changes in physiologic parameters such as ICP, practice varies considerably in this regard [
         <a href="#rid67">
          67,68
         </a>
         ]. In the absence of clinical deterioration, repeat imaging in six hours is reasonable in patients with a hematoma present on the initial scan, particularly in patients with a Glasgow Coma Scale (GCS) score &lt;9 [
         <a href="#rid69">
          69
         </a>
         ]. Although contrast is not typically used, parenchymal contrast extravasation, as with spontaneous intracerebral hemorrhage (ICH), may predict a higher risk of hemorrhage progression [
         <a href="#rid70">
          70
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1133.html" rel="external">
          "Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis", section on 'Predicting hemorrhage expansion'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Hemodynamic management
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fluids
         </strong>
         – Isotonic fluids (normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         ) should be used to maintain euvolemia. Saline may be preferable to albumin; the latter was associated with increased mortality (42 versus 22 percent, p &lt;0.001) in a post hoc analysis of patients with TBI enrolled in the SAFE clinical trial, which compared saline with albumin for fluid resuscitation in the intensive care unit (ICU) [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While balanced crystalloid solutions (eg,
         <a class="drug drug_general" data-topicid="108196" href="/z/d/drug information/108196.html" rel="external">
          lactated Ringer
         </a>
         's and plasmalyte) are used to decrease the risk of acute kidney injury in other critically ill patients, normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         is preferred in TBI, since balanced solutions are relatively hypotonic and may worsen cerebral edema. In the SMART ICU trial comparing saline with balanced solutions in the critically ill, exclusion of patients with TBI was permitted [
         <a href="#rid72">
          72
         </a>
         ]. Among the TBI patients enrolled in SMART ICU, no benefit was seen with the use of balanced fluids. Electrolyte imbalances are common in patients with TBI and should be regularly assessed along with other laboratory parameters.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blood pressure
         </strong>
         – The avoidance of hypotension remains a priority in the ICU. Guidelines recommend maintaining the systolic BP ≥100 mmHg for patients 50 to 69 years old and ≥110 mmHg for patients 15 to 49 or &gt;70 years old [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cerebral perfusion pressure
         </strong>
         – Through autoregulation, the normal cerebral vasculature maintains an adequate cerebral blood flow (CBF) across a wide range (50 to 150 mmHg) of mean arterial pressure (MAP). Cerebral autoregulation is disrupted in approximately one-third of patients with severe TBI [
         <a href="#rid73">
          73-75
         </a>
         ]. In these patients, a rise in MAP can lead to elevated ICP due to increased cerebral blood volume and hyperemia, while drops in MAP may be associated with hypoperfusion and ischemia. Patients with impaired cerebral autoregulation are described as "pressure passive."
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While optimization of CBF is a foundation of TBI treatment, bedside measurement of CBF is not easily obtained. Cerebral perfusion pressure (CPP), the difference between the MAP and the ICP (CPP = MAP – ICP), is a useful surrogate. Episodes of hypotension (low MAP), raised ICP, and/or low CPP are associated with secondary brain injury and worse clinical outcomes [
         <a href="#rid31">
          31,32,76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A goal CPP of 60 to 70 mmHg is recommended to improve survival and favorable outcomes [
         <a href="#rid15">
          15
         </a>
         ]. Targeting a goal CPP &gt;70 mmHg appeared to reduce mortality and morbidity in some earlier studies [
         <a href="#rid77">
          77,78
         </a>
         ]. However, subsequent studies have suggested that routine use of this strategy does not improve outcomes and may increase the risk of acute hypoxic respiratory failure [
         <a href="#rid78">
          78-80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Efforts to optimize CPP should first focus on treatment of ICP elevation [
         <a href="#rid81">
          81
         </a>
         ]. Patients with more severely impaired autoregulation and suboptimal CPP are best managed with efforts to lower ICP, rather than by elevating MAP with vasopressors; hypertension is more likely to worsen cerebral edema when protective autoregulation is impaired [
         <a href="#rid79">
          79
         </a>
         ]. (See
         <a class="local">
          'Intracranial pressure management'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Continuous monitoring of cerebral oximetry or the pressure reactivity index (PRx) may help determine the adequacy of autoregulation and identify the optimal CPP in individual patients. (See
         <a class="local">
          'Advanced neuromonitoring'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H583349274">
         <span class="h2">
          Ventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with severe TBI are sedated and artificially ventilated during the first several days [
         <a href="#rid82">
          82
         </a>
         ]. Since acute hypercarbia may result in elevations in ICP, and hypocarbia may precipitate cerebral ischemia, the use of end-tidal carbon dioxide (ETCO
         <sub>
          2
         </sub>
         ) monitoring should be considered for all ventilated TBI patients. Hypoxia should also be avoided, and the PaO
         <sub>
          2
         </sub>
         maintained &gt;60 mmHg [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         While hyperventilation can be used to reduce ICP, guidelines recommend avoiding hyperventilation because of safety concerns, especially in the acute phase (the first 24 to 48 hours) following TBI. Mild to moderate hyperventilation can be considered at later stages, but PaCO
         <sub>
          2
         </sub>
         of less than 30 mmHg should be avoided, except as a temporary intervention to help resolve ICP crises [
         <a href="#rid83">
          83
         </a>
         ]. (See
         <a class="local">
          'Patients with impending cerebral herniation'
         </a>
         below.)
        </p>
        <p>
         With hyperventilation, PaCO
         <sub>
          2
         </sub>
         decreases, leading to cerebral vasoconstriction, which then results in decreased cerebral blood volume and ICP. However, hyperventilation-induced vasoconstriction may also cause secondary ischemia and may thereby worsen outcomes [
         <a href="#rid84">
          84-86
         </a>
         ]. Hyperventilation can also increase extracellular lactate and glutamate levels that may contribute to secondary brain injury [
         <a href="#rid87">
          87
         </a>
         ]. In one randomized study, patients hyperventilated to a PaCO
         <sub>
          2
         </sub>
         of 25 mmHg for five days had a worse clinical outcome than nonhyperventilated controls [
         <a href="#rid88">
          88
         </a>
         ]. The use of multimodality monitoring of cerebral oxygenation and metabolism should also be considered when using therapeutic hyperventilation, to monitor its effects and prevent ischemic episodes [
         <a href="#rid85">
          85,86,89
         </a>
         ]. (See
         <a class="local">
          'Advanced neuromonitoring'
         </a>
         below.)
        </p>
        <p>
         While patients with TBI frequently suffer acute hypoxic respiratory failure and require higher levels of positive end-expiratory pressure (PEEP), a theoretical concern has been that elevated intrathoracic pressures will hamper venous return from the brain and worsen ICP. Studies of applied PEEP up to 15 to 20 cm H
         <sub>
          2
         </sub>
         O [
         <a href="#rid90">
          90-92
         </a>
         ], as well as ventilator modes such as airway pressure release ventilation (APRV) [
         <a href="#rid93">
          93
         </a>
         ], have not revealed a consistent effect on ICP, although patients with severe lung injury did demonstrate a small but statistically significant positive relationship between PEEP and ICP (0.31 mmHg rise in ICP for every 1 cm H
         <sub>
          2
         </sub>
         O rise in PEEP) in one retrospective study [
         <a href="#rid90">
          90
         </a>
         ]. The use of PEEP in TBI patients with acute respiratory distress syndrome (ARDS) does, however, seem to significantly improve brain tissue oxygenation [
         <a href="#rid92">
          92
         </a>
         ]. Our practice, therefore, is to use PEEP up to 15 to 20 cm H
         <sub>
          2
         </sub>
         O, as well as APRV when clinically appropriate, for the management of ARDS in patients with TBI in conjunction with monitoring of ICP.
        </p>
        <p class="headingAnchor" id="H1372647471">
         <span class="h2">
          Antiseizure medications and electroencephalography monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antiseizure medications are generally recommended to prevent and treat post-traumatic seizures in patients with TBI and any of the following: cortical contusion visible on CT scanning; a subdural, epidural, or intracerebral hematoma; a depressed skull fracture; a penetrating head wound; a seizure within 24 hours of injury; or a GCS score &lt;11 [
         <a href="#rid94">
          94,95
         </a>
         ]. We typically use
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         [
         <a href="#rid96">
          96
         </a>
         ]. Patients with TBI who develop any seizures will require ongoing antiseizure therapy. The duration of antiseizure medication therapy in severe TBI patients who do suffer seizures is not well established; this is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2213.html" rel="external">
          "Posttraumatic seizures and epilepsy", section on 'Management of early seizures'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for treatment and monitoring
         </strong>
         – The incidence of early post-traumatic seizures (within the first week or two) may be as high as 30 percent in patients with severe TBI [
         <a href="#rid97">
          97-99
         </a>
         ]. In addition, case series suggest that approximately 15 to 25 percent of patients with coma and severe head injury will have nonconvulsive seizures identified on continuous monitoring with electroencephalography (EEG) [
         <a href="#rid99">
          99-101
         </a>
         ]. While the clinical significance of clinically silent electrographic seizures is unclear, we monitor patients with EEG if there is persistent impaired consciousness that is disproportionate to the extent of injury visible on imaging. We generally continue antiseizure medications if there are electrographic seizures. The assessment and treatment of nonconvulsive status epilepticus are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/129547.html" rel="external">
          "Nonconvulsive status epilepticus: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The use of antiseizure medications in the acute management of TBI has been shown to reduce the incidence of early seizures but does not prevent the later development of epilepsy [
         <a href="#rid94">
          94,95
         </a>
         ]. In one trial of 404 patients with TBI and high seizure risk (ie, cortical contusion, intracranial hemorrhage, depressed skull fracture, penetrating injury, seizure within 24 hours, or GCS score &lt;11),
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         reduced the risk of seizures within the first week (3.6 versus 14.2 percent) [
         <a href="#rid94">
          94
         </a>
         ]. However, there was no reduction in the incidence of seizures at any subsequent time points up to two years after injury, and no difference in mortality.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Reasons to prevent early seizures include the risk of status epilepticus, which has a high fatality rate in this setting, and the potential of convulsions to aggravate a systemic injury [
         <a href="#rid99">
          99
         </a>
         ]. In addition, recurrent seizures may increase CBF and could thereby increase ICP. Another potential concern is that seizures place a metabolic demand on damaged brain tissue and may aggravate secondary brain injury.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of antiseizure medication
         </strong>
         – While certain guidelines recommend
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         to prevent early post-traumatic seizures for the first seven days following injury [
         <a href="#rid15">
          15
         </a>
         ], we prefer
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         in this setting.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Studies of
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         use in other conditions such as subarachnoid hemorrhage have revealed an adverse association between higher cumulative dosing of phenytoin and worse long-term functional and cognitive outcomes [
         <a href="#rid102">
          102
         </a>
         ]. A randomized clinical trial that compared
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         with phenytoin for seizure prophylaxis in neurosurgical ICU patients (89 percent with TBI) revealed equivalent efficacy for seizure prevention but improved six-month functional outcomes with levetiracetam [
         <a href="#rid96">
          96
         </a>
         ]. A subsequent single-center randomized clinical trial did not demonstrate a reduction in inpatient adverse events with levetiracetam compared with phenytoin, but did not assess long-term functional outcomes [
         <a href="#rid103">
          103
         </a>
         ]. A subsequent meta-analysis that included observational studies revealed fewer adverse drug events with levetiracetam [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Post-traumatic seizures and epilepsy are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2213.html" rel="external">
          "Posttraumatic seizures and epilepsy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1528748974">
         <span class="h2">
          Venous thromboembolism prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with TBI are at increased risk of venous thromboembolism (VTE). We initiate mechanical prophylaxis with intermittent pneumatic compression on admission for all patients with TBI, and chemoprophylaxis with either
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         5000 units three times daily or with
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         40 mg daily 24 hours following admission in most TBI patients with stability confirmed on repeat imaging.
        </p>
        <p>
         The efficacy and safety of mechanical thromboprophylaxis using intermittent pneumatic compression is discussed separately [
         <a href="#rid105">
          105,106
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"
         </a>
         .)
        </p>
        <p>
         While VTE risk can be further reduced with antithrombotic therapy, this has to be weighed against the potential risk of hemorrhage expansion, which is greatest in the first 24 to 48 hours [
         <a href="#rid107">
          107-109
         </a>
         ]. Data examining this trade-off in patients with severe TBI are limited. While some observational studies suggest that antithrombotic therapy may not be associated with increased risk of intracranial hemorrhage expansion [
         <a href="#rid110">
          110-112
         </a>
         ], others have found a higher rate of hemorrhage progression with the use of low molecular weight heparin [
         <a href="#rid113">
          113
         </a>
         ]. One pilot study randomly assigned 62 patients with low-risk TBI to
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         or placebo [
         <a href="#rid114">
          114
         </a>
         ]. Subclinical, radiographic progression of intracranial hemorrhage was nonsignificantly more common in the treated patient group; no patient suffered a clinical progression; one patient in the placebo group developed deep vein thrombosis (DVT). A more recent meta-analysis of clinical trials and observational studies concluded that the use of pharmacologic VTE prophylaxis was safe when initiated within 24 to 48 hours of injury in TBI patients with stability demonstrated on repeat imaging [
         <a href="#rid115">
          115
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1386685044">
         <span class="h2">
          Management of coagulopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Coagulation parameters should be measured in the emergency department (ED) in all patients with moderate or severe TBI, and efforts to correct any identified coagulopathy should begin immediately.
        </p>
        <p>
         Approximately one-third of patients with moderate or severe TBI demonstrate a coagulopathy, which is associated with an increased risk of hemorrhage enlargement, poor neurologic outcomes, and death [
         <a href="#rid116">
          116-121
         </a>
         ]. The coagulopathy may result from existing patient medications such as
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         or antiplatelet agents. Acute TBI is also thought to produce a more subtle coagulopathy through the systemic release of tissue factor and brain phospholipids into the circulation leading to inappropriate intravascular coagulation and a consumptive coagulopathy [
         <a href="#rid121">
          121-123
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients taking
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         may be managed with prothrombin complex concentrate (PCC) and
         <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">
          vitamin K
         </a>
         as recommended for patients with warfarin-associated ICH. (See
         <a class="medical medical_review" href="/z/d/html/1325.html" rel="external">
          "Reversal of anticoagulation in intracranial hemorrhage"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Reversal of direct oral anticoagulants is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">
          "Management of bleeding in patients receiving direct oral anticoagulants", section on 'Major bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with thrombocytopenia, some centers choose to maintain a platelet count &gt;75,000/microL with platelet transfusions if necessary. In one cohort analysis, a platelet count of &lt;135,000/microL was associated with a 12.4 times higher risk of hemorrhage expansion, while a platelet count of &lt;95,000/microL identified patients who were 31.5 times more likely to require neurosurgical intervention [
         <a href="#rid124">
          124
         </a>
         ]. There is insufficient evidence at this time to support the routine use of a specific goal platelet count.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The utility of platelet transfusions in TBI patients who arrive on antiplatelet medications is not known, although the incidence of neurologic worsening is greater in such patients [
         <a href="#rid124">
          124,125
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1615.html" rel="external">
          "Use of blood products in the critically ill", section on 'Platelets'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Recommendations for coagulation reversal in other categories of patients with moderate or severe TBI are limited by lack of evidence [
         <a href="#rid126">
          126
         </a>
         ]. When a coagulopathy is identified, it is reasonable to use fresh frozen plasma (FFP), PCC, and/or
         <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">
          vitamin K
         </a>
         as for
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         reversal. A reasonable, if somewhat arbitrary, target is an international normalized ratio (INR) &lt;1.4. A phase II dose-escalation clinical trial of recombinant factor VIIa in TBI patients demonstrated a nonsignificant trend towards limiting hematoma expansion but no mortality benefit, although this was not directed exclusively at patients with TBI-related INR elevation [
         <a href="#rid127">
          127
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10155" href="/z/d/drug information/10155.html" rel="external">
          Recombinant human factor VIIa
         </a>
         has not been shown to be of overall benefit in patients with nontraumatic ICH and is not used in the setting of traumatic ICH. (See
         <a class="medical medical_review" href="/z/d/html/1084.html" rel="external">
          "Spontaneous intracerebral hemorrhage: Acute treatment and prognosis", section on 'Reverse anticoagulation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H221186673">
         <span class="h2">
          Glucose management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Avoidance of both hypo- and hyperglycemia is appropriate in patients with moderate or severe TBI, but further studies are needed to clarify the optimal serum glucose target range and duration of therapy. To avoid extremes of very high or low blood glucose levels, we target a range of 140 to 180 mg/dL. (See
         <a class="medical medical_review" href="/z/d/html/1600.html" rel="external">
          "Glycemic control in critically ill adult and pediatric patients"
         </a>
         .)
        </p>
        <p>
         Both hyper- and hypoglycemia are associated with worsened outcome in a variety of neurologic conditions including severe TBI [
         <a href="#rid128">
          128-130
         </a>
         ]. This has been presumed to be at least in part related to aggravation of secondary brain injury. Several mechanisms for this are proposed, including increased tissue acidosis from anaerobic metabolism, free radical generation, and increased blood-brain barrier permeability.
        </p>
        <p>
         We do not use intensive insulin therapy to target a glucose level between 80 to 110 mg/dL. One case series using cerebral microdialysis found that tight glycemic control was associated with reduced cerebral glucose availability and elevated lactate:pyruvate ratio, which in turn was associated with increased mortality [
         <a href="#rid131">
          131
         </a>
         ]. Moreover, this approach is associated with a greater risk of hypoglycemia and worse outcomes in other critically ill patients. (See
         <a class="medical medical_review" href="/z/d/html/1600.html" rel="external">
          "Glycemic control in critically ill adult and pediatric patients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2755840110">
         <span class="h2">
          Temperature management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fever should be avoided. Fever is associated with worse outcome after stroke and probably severe head injury, presumably by aggravating secondary brain injury [
         <a href="#rid31">
          31
         </a>
         ]. Fever also worsens ICP control through an increase in metabolic demand, blood flow, and blood volume.
        </p>
        <p>
         Maintenance of normothermia should be attempted with the use of antipyretic medications, surface-cooling devices, or endovascular temperature management catheters. While induced normothermia using endovascular cooling and a continuous feedback-loop system has been shown to lower the fever burden and improve ICP control following TBI [
         <a href="#rid132">
          132
         </a>
         ], this approach has not been systematically tested with regard to clinical outcome. Our preference is to use surface cooling with adhesive pads and continuous feedback-loop regulation to maintain normothermia in patients with severe TBI and elevated ICP.
        </p>
        <p>
         Shivering may complicate these treatments and can increase metabolic demand and worsen brain tissue oxygenation [
         <a href="#rid133">
          133
         </a>
         ]. The management of shivering is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/127223.html" rel="external">
          "Intensive care unit management of the intubated post-cardiac arrest adult patient", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
         Noninduced hypothermia has been associated with an increase in mortality after TBI [
         <a href="#rid134">
          134
         </a>
         ], but the efficacy of efforts to avoid this complication has not been evaluated.
        </p>
        <p>
         The role of therapeutic induced hypothermia is discussed separately. (See
         <a class="local">
          'Hypothermia'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H544422138">
         <span class="h2">
          Paroxysmal sympathetic hyperactivity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Occurring in approximately 10 percent of patients with severe TBI, paroxysmal sympathetic hyperactivity (PSH) is characterized by episodes of hypertension, tachycardia, tachypnea, hyperthermia, diaphoresis, increased tone, and posturing of varying severity that are often but not always triggered by external stimuli.
        </p>
        <p>
         Depending on the symptom complex, other conditions, such as pulmonary embolism, may need to be excluded. Appropriate management includes avoiding those stimuli that provoke attacks and a combination of abortive and preventive medications.
        </p>
        <p>
         The diagnosis and management of PSH are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/122115.html" rel="external">
          "Paroxysmal sympathetic hyperactivity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2240049226">
         <span class="h2">
          Nutritional support
         </span>
         <span class="headingEndMark">
          —
         </span>
         Guidelines recommend that basic nutritional goals be attained no later than five to seven days from injury, and that transpyloric enteral nutrition be considered to decrease the rate of ventilator-associated pneumonia [
         <a href="#rid15">
          15,135
         </a>
         ]. There is some evidence that early enteral nutrition may decrease rates of pneumonia [
         <a href="#rid136">
          136
         </a>
         ] as well as mortality [
         <a href="#rid137">
          137
         </a>
         ] following TBI, although a randomized controlled trial did not demonstrate a reduction in complications [
         <a href="#rid138">
          138
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1617.html" rel="external">
          "Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          INTRACRANIAL PRESSURE MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Elevated intracranial pressure (ICP) is associated with increased mortality and worse outcome [
         <a href="#rid139">
          139-141
         </a>
         ].
        </p>
        <p>
         Specific measures regarding ICP management in the setting of TBI are discussed here. The evaluation and management of elevated ICP in other settings are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1659.html" rel="external">
          "Evaluation and management of elevated intracranial pressure in adults"
         </a>
         .)
        </p>
        <p>
         A tiered approach to management of elevated ICP in severe TBI is shown in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef121359" href="/z/d/graphic/121359.html" rel="external">
          algorithm 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H590588248">
         <span class="h2">
          Initial (baseline) treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Simple techniques should be instituted as soon as possible:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Head of bed (HOB) elevation to 30° to permit adequate venous drainage from the brain while not compromising cerebral perfusion
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Optimization of venous drainage: keeping the neck in neutral position, loosening neck braces if too tight
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H693579074">
         <span class="h2">
          Patients with impending cerebral herniation
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients should be quickly assessed for impending cerebral herniation; such assessments are typically performed every one to two hours in the first few days after moderate or severe TBI. Clinical signs of impending herniation include significant pupillary asymmetry, unilateral or bilateral fixed and dilated pupils, decorticate or decerebrate posturing, respiratory depression, and the "Cushing triad" of hypertension, bradycardia, and irregular respiration. In such patients, the following measures must be taken immediately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endotracheal intubation, if not already performed, keeping in mind the specific considerations outlined above. (See
         <a class="local">
          'Emergency department'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevation of the HOB to 30 to 45°, with the head maintained in the neutral position, to permit adequate venous drainage from the brain while not compromising cerebral perfusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Brief hyperventilation to a pCO
         <sub>
          2
         </sub>
         of approximately 30 mmHg (end-tidal carbon dioxide [ETCO
         <sub>
          2
         </sub>
         ] 25 to 30 mmHg), as a lifesaving measure. Hyperventilation will rapidly and reliably lower the ICP in the setting of cerebral herniation [
         <a href="#rid48">
          48
         </a>
         ]. However, prolonged use is potentially harmful and is not recommended. (See
         <a class="local">
          'Ventilation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of a bolus dose of an osmotic agent capable of transiently reversing cerebral herniation. The two agents that have demonstrated efficacy in published studies to acutely reverse herniation are:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          Mannitol
         </a>
         : 1 to 1.5 g/kg [
         <a href="#rid142">
          142
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         23.4 percent sodium chloride (NaCl): 30 to 60 mL administered over 10 minutes [
         <a href="#rid143">
          143
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Since
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         may result in volume depletion, we prefer 23.4 percent NaCl, particularly in trauma patients with ongoing blood loss, hemodynamic instability, or renal failure. Excessively rapid administration of 23.4 percent NaCl can, however, provoke transient but profound hypotension [
         <a href="#rid143">
          143
         </a>
         ]. While the administration of 23.4 percent NaCl through central venous access is preferred, this agent may be administered safely via peripheral venous access in life-threatening situations such as impending or ongoing cerebral herniation and severe ICP elevation [
         <a href="#rid144">
          144
         </a>
         ]. Guidelines recommend that mannitol use prior to the initiation of ICP monitoring be restricted to the management of cerebral herniation or acute neurologic deterioration that is not attributable to extracranial causes [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maintenance of a higher mean arterial pressure (MAP), to approximately 80 to 100 mmHg, to maintain an adequate cerebral perfusion pressure (CPP), since the ICP may be extremely high in the setting of cerebral herniation. Both fluid resuscitation and vasopressor use are frequently necessary in this setting.
        </p>
        <p>
        </p>
        <p>
         Such interventions are a temporizing measure pending more definitive interventions, including neurosurgical treatment.
        </p>
        <p class="headingAnchor" id="H2618084422">
         <span class="h2">
          ICP and CPP monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Current Brain Trauma Foundation (BTF) guidelines recommend that information from ICP monitoring be used to guide the management of patients with severe TBI (Glasgow Coma Scale [GCS] score &lt;9) in order to reduce in-hospital and two-week postinjury mortality [
         <a href="#rid15">
          15
         </a>
         ]. We recommend the use of ICP monitoring in patients with moderate TBI without a reliable neurologic examination because of prolonged sedation or anesthesia within the first 48 hours of injury, and in patients who suffer neurologic worsening to GCS score &lt;9.
        </p>
        <p>
         A ventricular catheter, also known as an external ventricular drain (EVD), connected to a strain gauge transducer is the most accurate and cost-effective method of ICP monitoring and has the therapeutic advantage of allowing for cerebrospinal fluid (CSF) drainage to treat rises in ICP  (
         <a class="graphic graphic_figure graphicRef56391" href="/z/d/graphic/56391.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid145">
          145
         </a>
         ]. Intraparenchymal ICP monitors are technically easier to place and are associated with a lower risk of hemorrhage and infection than EVDs. An intraparenchymal catheter may be an acceptable alternative when the risk of bleeding or infection is thought to be higher than usual, or when EVD placement is unsuccessful because of technical difficulty. Significant midline shift and ventricular collapse ("slit ventricles") will increase the technical difficulty of EVD placement. Intraparenchymal catheters permit continuous monitoring of ICP, while most EVDs only permit measurement of ICP when the stopcock is closed to CSF drainage and open to the transducer. Intraparenchymal catheters may therefore be utilized in conjunction with an EVD when continuous CSF drainage is performed. Intraparenchymal catheters have been preferentially used for ICP monitoring of severe TBI patients in some resource-limited settings because of the perceived high baseline risk of infection [
         <a href="#rid146">
          146,147
         </a>
         ]. However, low-cost techniques of external ventricular drainage for ICP monitoring are also recommended in these settings [
         <a href="#rid148">
          148
         </a>
         ]. Other monitor types are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1659.html" rel="external">
          "Evaluation and management of elevated intracranial pressure in adults", section on 'Types of monitors'
         </a>
         .)
        </p>
        <p>
         An ICP goal ≤22 mmHg is recommended as the threshold that predicts survival and favorable outcome following TBI [
         <a href="#rid15">
          15,149
         </a>
         ]. Therapeutic measures are initiated in a stepwise manner to attain this goal, starting with CSF drainage, sedation, and analgesia as described in sections below.
        </p>
        <p>
         ICP monitoring allows ongoing assessment of CPP, itself an approximation of the more clinically relevant cerebral blood flow (CBF). Targeting a goal CPP of 60 to 70 mmHg appears to reduce mortality and morbidity [
         <a href="#rid15">
          15,77,78
         </a>
         ]. Efforts to optimize CPP should first focus on treatment of ICP elevations [
         <a href="#rid81">
          81
         </a>
         ]. Patients with more severely impaired autoregulation and suboptimal CPP are best managed with efforts to lower ICP, rather than by elevating MAP with vasopressors; hypertension is more likely to worsen cerebral edema when protective autoregulation is impaired [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         While ICP monitoring has long been central to the management of patients with severe head injury, the strength of this recommendation has been limited by the lack of large randomized trials examining the effect of ICP monitoring and treatment on outcome [
         <a href="#rid150">
          150-152
         </a>
         ]. One randomized study of 324 patients older than 12 years with severe TBI hospitalized in Bolivia or Ecuador (BEST TRIP) found no differences in outcomes among those patients assigned to management guided by invasive ICP monitoring consistent with guidelines versus patients assigned to a treatment protocol based on high-intensity clinical and imaging evaluation [
         <a href="#rid146">
          146
         </a>
         ]. While this trial demonstrated the feasibility of managing patients in low-resource environments using frequent clinical and imaging evaluations, as an alternative to invasive ICP monitoring, its findings are not considered to be generalizable to the management of severe TBI in other settings. Other important limitations of the trial include limited use of CSF drainage, multiple statistically significant differences in therapeutic measures between treatment arms that may have impacted outcomes, and limitations in the availability of rehabilitative services following discharge. By contrast, registry-based studies from New York and India [
         <a href="#rid147">
          147,153
         </a>
         ] have demonstrated decreased in-hospital mortality with the use of invasive ICP monitoring to guide therapy, even after controlling for potential confounders.
        </p>
        <p>
         Several noninvasive techniques of ICP monitoring have been evaluated [
         <a href="#rid154">
          154
         </a>
         ]. Sonographic measurement of the optic nerve sheath diameter (ONSD) has shown promise in some studies [
         <a href="#rid155">
          155-157
         </a>
         ]; however, prespecified thresholds of diagnostic accuracy were not met in a subsequent prospective study of 120 patients with severe TBI and concomitant invasive ICP monitoring evaluated with ONSD [
         <a href="#rid158">
          158
         </a>
         ]. Transcranial Doppler has also been evaluated for noninvasive ICP assessment, with variable results [
         <a href="#rid159">
          159-161
         </a>
         ]. All of these techniques are currently considered investigational and should not be used to direct clinical management.
        </p>
        <p class="headingAnchor" id="H580642389">
         <span class="h2">
          Cerebrospinal fluid drainage
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with a ventricular catheter, drainage of CSF is generally the first intervention for lowering ICP. Drainage may be continuous or intermittent, with a limited volume of CSF drained in response to elevations in ICP above goal.
        </p>
        <p>
         Based on observational data, guidelines recommend continuous CSF drainage for better control of ICP compared with intermittent drainage [
         <a href="#rid15">
          15,162
         </a>
         ]. Continuous drainage is particularly recommended in patients with a GCS score &lt;6 in the first 12 hours [
         <a href="#rid15">
          15
         </a>
         ]. Caution must be utilized with continuous drainage, however, since excessive drainage can lead to ventricular collapse and malfunctioning or occlusion of the catheter in the setting of cerebral edema and small ventricles.
        </p>
        <p class="headingAnchor" id="H228046375">
         <span class="h2">
          Sedation and analgesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Protocol-based analgosedation is recommended by 2018 guidelines from the Society of Critical Care Medicine to decrease duration of mechanical ventilation and intensive care unit (ICU) length of stay [
         <a href="#rid163">
          163
         </a>
         ]. Analgosedation may consist of either analgesia-first sedation or analgesia-based sedation. With analgesia-first sedation, an opioid such as
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         is used before, then often in conjunction with, a sedative infusion to achieve sedation goals. Analgesia-based sedation consists of the use of an opioid infusion alone, titrated to high enough doses to achieve a sedation goal without a concomitant sedative infusion. While either approach is a reasonable first step in the management of the intubated patient with severe TBI, patients with significant ICP elevation should be managed with an effective sedative agent in conjunction with the opioid infusion. Appropriate analgesia and sedation may lower ICP by reducing cerebral metabolic demand, and thereby CBF and cerebral blood volume [
         <a href="#rid164">
          164
         </a>
         ]. Sedation may also ameliorate ventilator asynchrony and blunt sympathetic responses of hypertension and tachycardia.
        </p>
        <p>
         Effective analgesia is a critical first step, since patients with TBI often have pain that goes unrecognized.
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          Fentanyl
         </a>
         infusions are commonly used in this setting for greater efficacy compared with
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         , and to minimize hemodynamic instability. (See
         <a class="medical medical_review" href="/z/d/html/2888.html" rel="external">
          "Pain control in the critically ill adult patient"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          Propofol
         </a>
         may be the preferred sedating agent in this setting because of its efficacy in decreasing cerebral metabolic demand and ICP, as well as its short duration of action that allows intermittent clinical neurologic assessment [
         <a href="#rid165">
          165
         </a>
         ]. In one trial, propofol appeared to be associated with better ICP control and a trend toward better outcomes compared with
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         alone [
         <a href="#rid166">
          166
         </a>
         ]. Propofol also has putative neuroprotective effects [
         <a href="#rid167">
          167
         </a>
         ]. Hypotension is common with propofol, and fluids and vasopressors should be used as appropriate to maintain CPP goals. The propofol infusion syndrome (severe metabolic acidosis, rhabdomyolysis, hyperkalemia, renal failure, and cardiovascular collapse) is a rare complication that is more likely to occur with the use of high rates of infusion over extended periods of time [
         <a href="#rid168">
          168
         </a>
         ]. Other considerations in the selection of sedative agents in the critical care setting are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">
          "Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal"
         </a>
         .)
        </p>
        <p>
         In general, light sedation, to a goal Richmond Agitation-Sedation Scale (RASS)  (
         <a class="graphic graphic_table graphicRef57874" href="/z/d/graphic/57874.html" rel="external">
          table 3
         </a>
         ) of 0 to -2, is recommended when the ICP is adequately controlled [
         <a href="#rid164">
          164
         </a>
         ]. Deeper levels of sedation, to a RASS of -4 to -5, are often necessary when ICP elevation is refractory to light sedation.
        </p>
        <p>
         Dosing and administration of sedative and analgesic agents in the critical care setting is described in detail separately  (
         <a class="graphic graphic_table graphicRef79667" href="/z/d/graphic/79667.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">
          "Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects"
         </a>
         .)
        </p>
        <p>
         Neuromuscular blockade may decrease ICP elevations associated with ventilator dyssynchrony and coughing. However, the routine use of paralytic medications is discouraged, since these agents may result in prolonged neuromuscular weakness and delay weaning from mechanical ventilation. (See
         <a class="medical medical_review" href="/z/d/html/5144.html" rel="external">
          "Neuromuscular weakness related to critical illness"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Osmotic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Osmotic therapy (
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         or hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         ) is generally utilized in TBI patients who are clinically symptomatic from cerebral edema or have documented ICP elevation that does not respond to initial measures such as CSF drainage, analgesia, and sedation.
        </p>
        <p>
         Intravascular injection of hyperosmolar agents (hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         ) creates an osmolar gradient, drawing water across the blood-brain barrier [
         <a href="#rid169">
          169
         </a>
         ]. This leads to a decrease in brain volume and a decrease in ICP.
        </p>
        <p class="headingAnchor" id="H3872472492">
         <span class="h3">
          Protocols
         </span>
         <span class="headingEndMark">
          —
         </span>
         We use an infusion of 3 percent NaCl to achieve a sodium goal of 145 to 155 mEq/L in patients with elevated ICP. In addition, we use supplemental 30 mL bolus doses of 23.4 percent NaCl, administered over 10 minutes, to treat acute ICP elevations.
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          Mannitol
         </a>
         is an acceptable alternative. No specific hyperosmolar treatment protocol has been shown to improve function outcome or mortality in clinical trials.
        </p>
        <p>
         The effect of hyperosmolar therapy diminishes with time, as a compensatory increase in brain osmoles occurs within 24 hours [
         <a href="#rid170">
          170,171
         </a>
         ]. Thus, hyperosmolar agents should be weaned slowly after prolonged use to prevent a reversal in the osmotic gradient and consequent rebound cerebral edema.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypertonic
         </strong>
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         is an effective hyperosmolar agent for the control of elevated ICP [
         <a href="#rid93">
          93,147,170,172-181
         </a>
         ]. This agent has been used in a wide range of concentrations, from 3 percent, most commonly used as a continuous infusion, to 23.4 percent, which is typically used in intermittent boluses [
         <a href="#rid182">
          182,183
         </a>
         ]. When used as a continuous infusion, 3 percent NaCl may be titrated to an initial sodium goal of approximately 145 to 155 mEq/L. Hypertonic saline should be administered via a central venous catheter because of the risk of extravasation injury when used with peripheral intravenous (IV) access. Short-term use via peripheral IV access is permissible in the setting of acute ICP elevation, however, while central access is obtained.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         has several theoretical advantages over
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         [
         <a href="#rid170">
          170
         </a>
         ]. In particular, volume depletion and hypovolemia do not occur, which makes this agent safer in the trauma patient with ongoing blood loss, hypovolemia, or hypotension. Hypertonic saline has a reflection coefficient of 1.0 (compared with 0.9 for mannitol), and is therefore less likely to leak into brain tissue. Potential adverse effects include circulatory overload and pulmonary edema, and an increased chloride burden, which may result in a non-anion gap metabolic acidosis [
         <a href="#rid184">
          184
         </a>
         ]. (See
         <a class="local">
          'Monitoring and complications'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          Mannitol
         </a>
         has also been shown to reduce ICP and improve CBF [
         <a href="#rid151">
          151,185-189
         </a>
         ]. Mannitol is administered in boluses of 0.25 to 1 g/kg every four to six hours as needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A serious albeit theoretical concern with
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         use is leakage into brain tissue in patients with disruption of the blood-brain barrier, with consequent reversal of the osmolar gradient and rebound cerebral edema [
         <a href="#rid190">
          190,191
         </a>
         ]. Judicious administration of mannitol, on an as-needed basis for elevations in ICP, is advisable to minimize this potential risk. (See
         <a class="medical medical_review" href="/z/d/html/1659.html" rel="external">
          "Evaluation and management of elevated intracranial pressure in adults", section on 'Mannitol'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In the aggregate, multiple observational studies [
         <a href="#rid177">
          177,180
         </a>
         ], small randomized clinical trials [
         <a href="#rid172">
          172,173,178,181
         </a>
         ], meta-analyses [
         <a href="#rid175">
          175,179
         </a>
         ], and systematic reviews [
         <a href="#rid176">
          176
         </a>
         ] have not found compelling evidence to suggest superiority of either agent to improve outcomes such as mortality or functional recovery. The majority of studies do suggest improved ICP control with hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         [
         <a href="#rid172">
          172,173,176-180
         </a>
         ], along with possible improvements in cerebral perfusion [
         <a href="#rid178">
          178,180
         </a>
         ] and brain tissue oxygenation [
         <a href="#rid180">
          180
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4152219321">
         <span class="h3">
          Monitoring and complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serial measurement of electrolytes, often at four- to six-hour intervals, is primarily performed for safety, to prevent excessive elevation of sodium and chloride levels, and to detect and correct other derangements such as hypokalemia. Ongoing fluid balance should also be closely monitored. Hypernatremia is associated with increased mortality in severe TBI [
         <a href="#rid192">
          192
         </a>
         ]. This association may reflect an effect of diabetes insipidus (DI) [
         <a href="#rid192">
          192
         </a>
         ], often a marker of more extensive brain injury that includes the hypothalamic-pituitary axis.
        </p>
        <p>
         In addition, for patients receiving
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         , serum osmolality should be monitored and maintained &lt;320 mmol/L to minimize complications. Renal function tests are checked daily. As an osmotic diuretic, mannitol may cause dehydration and acute kidney injury. (See
         <a class="medical medical_review" href="/z/d/html/2333.html" rel="external">
          "Complications of mannitol therapy"
         </a>
         .)
        </p>
        <p>
         Hypernatremia should be corrected gradually, if at all. Severe rebound cerebral edema may occur when the sodium level, and therefore serum osmolality, is lowered too quickly. There is no high-quality evidence for a specific upper limit of sodium that necessitates correction in this setting, and management should be individualized. Patients with renal failure may be at higher risk for complications from hyperchloremia [
         <a href="#rid72">
          72
         </a>
         ]. Patients with DI should also be managed more aggressively, primarily to treat hypovolemia and the free water deficit. (See
         <a class="medical medical_review" href="/z/d/html/2313.html" rel="external">
          "Arginine vasopressin deficiency (central diabetes insipidus): Treatment"
         </a>
         .)
        </p>
        <p>
         In the absence of these conditions and in the setting of elevated ICP or severe cerebral edema, we rarely correct a sodium level under 160 to 165 mEq/L. When the sodium level is lowered, we avoid correction by more than 5 mEq/L in a 24-hour period, and we closely monitor the patient's neurologic status and ICP. (See
         <a class="medical medical_review" href="/z/d/html/2339.html" rel="external">
          "Treatment of hypernatremia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1623425662">
         <span class="h2">
          Refractory ICP elevation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with elevated ICP that is refractory to the measures described above may be managed with decompressive craniectomy, barbiturate coma, or hypothermia.
        </p>
        <p class="headingAnchor" id="H209157440">
         <span class="h3">
          Decompressive craniectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Decompressive craniectomy is effective in controlling ICP and is potentially lifesaving in patients who have failed medical therapy. Guidelines recommend the use of decompressive craniectomy in patients with severe TBI and ICP elevation above goal for &gt;1 to 12 hours despite the use of at least two tiers of medical therapy (late refractory ICP elevation) [
         <a href="#rid193">
          193
         </a>
         ]. While many patients who require decompressive craniectomy as a lifesaving procedure will suffer severe disability, some survivors will attain a functional outcome of independence within the home or better.
        </p>
        <p>
         In a decompressive craniectomy, a substantial portion of the skull is removed to allow brain tissue to swell beyond the confines of the cranial vault, which otherwise restricts the total volume contained within (the Monro-Kellie doctrine). A craniectomy of sufficient size can rapidly relieve intracranial hypertension. A "primary" or prophylactic craniectomy is performed in anticipation of elevated ICP, most often at the time of hematoma evacuation, or on the basis of clinical or imaging findings on presentation that suggest the presence of life-threatening intracranial hypertension [
         <a href="#rid194">
          194,195
         </a>
         ]. A "secondary" or therapeutic decompressive craniectomy is performed to control proven ICP elevation (measured using invasive monitoring) that is refractory to medical therapy.
        </p>
        <p>
         Attention to specific technical considerations is particularly important [
         <a href="#rid194">
          194,195
         </a>
         ], since an ineffective decompression will expose the patient to the risks of the procedure without the anticipated benefit:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The site and extent of bone removal should be tailored to the predominant location of injury and edema. A hemicraniectomy (removal of one side of the skull) is performed for predominantly unilateral injury, while a large bifrontal craniectomy, with variable extension into the temporal and parietal bones, is necessary for bifrontal or diffuse injury.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The craniectomy must be of sufficient size. An insufficient skull defect may be ineffective in resolving intracranial hypertension, while causing additional injury when cortical veins are compressed against the edge of the skull defect, leading to venous infarction. Two randomized clinical trials have demonstrated a reduction in poor long-term functional outcome with the use of larger compared with more limited decompressive craniectomy [
         <a href="#rid196">
          196,197
         </a>
         ]. Guidelines recommend a large frontotemporoparietal decompressive craniectomy (not less than 12 × 15 cm or 15 cm in diameter) over a smaller frontotemporoparietal craniectomy to decrease mortality and improve neurologic outcomes [
         <a href="#rid193">
          193
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The middle cranial fossa should be adequately decompressed to minimize the risk of uncal herniation, which may occur despite normal ICP.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A generous durotomy must be performed, since most of the reduction in ICP is achieved by opening the dura. The dural defect is then covered using loosely applied hemostatic material or a duraplasty.
        </p>
        <p>
        </p>
        <p>
         Clinical trials of decompressive craniectomy in TBI suggest that the procedure is effective in controlling ICP and is lifesaving in patients who have failed medical therapy. However, patients who require decompressive craniectomy for the management of intracranial hypertension following TBI have suffered particularly severe brain injury and may be left in a state of severe disability or worse. Conclusions from clinical trials are somewhat limited because of short follow-up time; functional recovery following severe TBI may be delayed beyond one year of follow-up. (See
         <a class="local">
          'Outcomes'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A randomized trial (DECRA) in 155 adults with severe diffuse TBI and ICP &gt;20 mmHg for 15 minutes within a one-hour period despite first-tier therapies compared bifrontal craniectomy with continued medical care [
         <a href="#rid198">
          198
         </a>
         ]. Surgery was associated with a decreased burden of intracranial hypertension and shorter stays in the ICU, but worse outcome on the extended Glasgow Outcome Scale (E-GOS) at six months. Patients judged to require surgical evacuation of an intracranial hematoma were excluded, limiting the applicability of these findings. Other limitations of this trial included a low ICP threshold for eligibility, use of a very extensive bilateral craniectomy not reflective of typical clinical practice, and a baseline imbalance in patients admitted with bilateral fixed pupils suggestive of devastating injury [
         <a href="#rid199">
          199
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The RESCUEicp trial used more broadly applicable eligibility criteria; 408 patients 10 to 65 years old with refractory ICP &gt;25 mmHg for 1 to 12 hours despite medical therapy were randomized to continued medical therapy or craniectomy appropriate to the type of injury [
         <a href="#rid200">
          200
         </a>
         ]. Patients requiring hematoma evacuation were included. Control of ICP was improved in the surgical arm. At six months, patients in the surgical group had lower mortality (27 versus 49 percent) but higher rates of vegetative state (8.5 versus 2.1 percent), lower severe disability (dependent on others for care in the home; 22 versus 14 percent), and upper severe disability (independent within but not outside of the home; 15 versus 8 percent), these outcomes likely reflecting those of patients who would have not otherwise survived. Rates of moderate disability and good recovery were similar between the two groups (23 versus 20 percent and 4 versus 7 percent, respectively). The intention-to-treat analysis with 37 percent crossover from medical to surgical treatment likely diluted the apparent treatment effect. A prespecified analysis of outcomes at one year revealed that the surgical group had a higher rate of favorable outcomes (defined as better than lower severe disability or, ie, functionally independent within the home or better) of 45 versus 32 percent.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1048269108">
         <span class="h3">
          Barbiturate coma
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9754" href="/z/d/drug information/9754.html" rel="external">
          Pentobarbital
         </a>
         and thiopental infusions may be used to manage elevated ICP refractory to other therapies. While effective for the control of ICP, the use of barbiturate coma has not been shown to improve outcomes following TBI [
         <a href="#rid201">
          201
         </a>
         ]. Our practice is to consider barbiturate coma for ICP control only when first-line measures, including hyperosmolar therapy as well as a
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         infusion titrated to deep sedation (RASS score of -5), have been ineffective and surgical decompression is not feasible.
        </p>
        <p>
         These agents profoundly decrease cerebral metabolic demand, CBF, and cerebral blood volume [
         <a href="#rid202">
          202
         </a>
         ]. A loading dose of 5 to 20 mg/kg of
         <a class="drug drug_general" data-topicid="9754" href="/z/d/drug information/9754.html" rel="external">
          pentobarbital
         </a>
         is typically administered, followed by 1 to 4 mg/kg per hour. Continuous EEG monitoring is used, with the pentobarbital infusion titrated to produce a burst-suppression pattern. While effective for the control of ICP, pentobarbital infusions are associated with morbidity. The neurologic examination is precluded for an extended period of time because of the long half-life of this drug. This may also result in delays in the determination of brain death. Other common side effects include hypotension requiring vasopressor support, adynamic ileus, and poor pulmonary mucus clearance, with the consequent risk of ventilator-associated pneumonia [
         <a href="#rid203">
          203
         </a>
         ]. Severe metabolic acidosis from propylene-glycol toxicity has been reported with the use of pentobarbital infusions [
         <a href="#rid204">
          204,205
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2105068792">
         <span class="h3">
          Hypothermia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Induced or therapeutic hypothermia has been proposed as a treatment for TBI based upon its potential to reduce ICP as well as to provide neuroprotection and prevent secondary brain injury [
         <a href="#rid206">
          206
         </a>
         ]. Therapeutic hypothermia does appear effective for the control of ICP [
         <a href="#rid207">
          207
         </a>
         ] but has not been convincingly shown to improve outcomes. Therapeutic hypothermia treatment should, therefore, be limited to clinical trials, or to patients with elevated ICP refractory to other therapies, after discussion with family and other patient surrogates [
         <a href="#rid208">
          208-210
         </a>
         ].
        </p>
        <p>
         A systematic review of 37 randomized controlled trials, including 3110 subjects, of mild to moderate hypothermia (32 to 35°C) following TBI concluded that there was no high-quality evidence that hypothermia is beneficial following TBI for the goal of improving meaningful long-term outcomes [
         <a href="#rid211">
          211
         </a>
         ]. Other systematic reviews and meta-analyses found borderline benefits for death and neurologic outcome, but also an increased risk for pneumonia [
         <a href="#rid206">
          206,212-215
         </a>
         ]. Substantial variability among studies in the depth and duration of hypothermia, as well as the rate of rewarming, limits the ability to draw conclusions from these studies. Two subsequently published trials found no benefit of induced hypothermia in specific subgroups of patients with TBI; in one, hypothermia was not beneficial when initiated within two to five hours of TBI in a selected group of younger patients (age 16 to 45 years) [
         <a href="#rid216">
          216
         </a>
         ]. In another trial, there was no benefit for induced hypothermia when added to other standard-of-care measures in patients with intracranial hypertension refractory to initial treatment within 10 days of TBI; deaths and unfavorable outcomes were somewhat more common in patients receiving therapeutic hypothermia [
         <a href="#rid217">
          217
         </a>
         ].
        </p>
        <p>
         Two trials of hypothermia therapy in children with TBI have shown no improvement in neurologic or other outcomes; one showed a nonsignificant increase in mortality [
         <a href="#rid218">
          218,219
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/106112.html" rel="external">
          "Elevated intracranial pressure (ICP) in children: Management", section on 'Temperature control'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2450277036">
         <span class="h1">
          ADVANCED NEUROMONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         In order to supplement intracranial pressure (ICP) monitoring, several technologies have been developed for the treatment of severe TBI. These techniques allow for the measurement of cerebral physiologic and metabolic parameters related to oxygen delivery, cerebral blood flow (CBF), and metabolism, with the goal of improving the detection and management of secondary brain injury.
        </p>
        <p>
         While observational data suggest that these monitoring tools provide unique information that may help to individualize the management of patients with severe head injury, clinical trial data demonstrating improved outcomes with use of these multimodality advanced neuromonitoring approaches are awaited.
        </p>
        <p>
         Such techniques include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Jugular venous oximetry – Retrograde cannulation of the internal jugular vein that allows measurement of oxygen saturation in the blood exiting the brain [
         <a href="#rid220">
          220
         </a>
         ]. Normal jugular venous oxygen saturation (SjVO
         <sub>
          2
         </sub>
         ) is approximately 60 percent. SjVO
         <sub>
          2
         </sub>
         &lt;50 percent for 10 minutes is considered a "cerebral desaturation" and implies a mismatch between oxygen delivery and demand in the brain. These desaturation episodes are associated with unfavorable neurologic outcomes in this setting [
         <a href="#rid15">
          15,221,222
         </a>
         ]. Jugular venous oximetry protocols that specify stepwise escalation of therapy to improve cerebral perfusion when desaturations occur have been used at several institutions; however, randomized clinical trials have not been performed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Brain tissue oxygen tension (PbtO
         <sub>
          2
         </sub>
         ) monitoring – Intraparenchymal oxygen electrode placed in a manner similar to a fiberoptic ICP probe that measures PbtO
         <sub>
          2
         </sub>
         in the white matter [
         <a href="#rid223">
          223
         </a>
         ]. Normal PbtO
         <sub>
          2
         </sub>
         is &gt;20 mmHg; duration and depth of PbtO
         <sub>
          2
         </sub>
         below 15 mmHg are associated with worsened outcome [
         <a href="#rid224">
          224
         </a>
         ]. Some studies have shown improved outcomes in patients managed with treatment protocols directed at optimization of PbtO
         <sub>
          2
         </sub>
         as compared with historical controls [
         <a href="#rid225">
          225,226
         </a>
         ]. A phase 2 randomized clinical trial (BOOST-2) demonstrated the feasibility of a goal-directed management protocol for the optimization of PbtO
         <sub>
          2
         </sub>
         following TBI [
         <a href="#rid227">
          227
         </a>
         ]; a phase 3 trial (BOOST-3) is underway.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cerebral microdialysis – Intraparenchymal probe placed in a manner similar to a PbtO
         <sub>
          2
         </sub>
         probe that allows measurement of extracellular glucose, lactate, pyruvate, and glutamate [
         <a href="#rid228">
          228,229
         </a>
         ]. A lactate:pyruvate ratio &gt;40 is suggestive of anaerobic metabolism, which is believed to exacerbate secondary brain injury.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thermal diffusion flowmetry – Intraparenchymal probe placed in a manner similar to a PbtO
         <sub>
          2
         </sub>
         probe that allows continuous measurement of CBF, usually in the white matter. Correlation with CBF from neuroimaging and outcome data is very preliminary at present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pressure reactivity index (PRx) – The continuously monitored moving correlation coefficient between mean ICP and mean arterial pressure (MAP), used as a measure of cerebral autoregulation. A direct correlation of ICP with MAP, with a PRx close to +1.0, suggests the absence of cerebral autoregulation and may be seen with refractory intracranial hypertension. PRx thresholds of 0.25 and 0.05, suggesting the presence of robust cerebral autoregulation, predicted survival and favorable outcome, respectively, in one study [
         <a href="#rid149">
          149
         </a>
         ]. The PRx has also been used to identify optimal cerebral perfusion pressure (CPP) [
         <a href="#rid230">
          230
         </a>
         ] and ICP [
         <a href="#rid231">
          231
         </a>
         ] goals in individual TBI patients based on quantification of cerebral autoregulation.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3250750809">
         <span class="h1">
          INTERVENTIONS WITH UNCERTAIN OR NO BENEFIT
         </span>
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h2">
          Neuroprotective treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         A wide range of agents targeting various aspects of the brain injury cascade has been tested in clinical trials. To date, no neuroprotective agents or strategies (including induced hypothermia) have been shown to produce improved outcome [
         <a href="#rid232">
          232
         </a>
         ]. No benefit was found for intravenous (IV)
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         administration in two randomized trials in acute severe TBI [
         <a href="#rid233">
          233,234
         </a>
         ]. Citicoline was not found to be effective at improving outcomes in a randomized trial of 1213 patients with TBI [
         <a href="#rid235">
          235
         </a>
         ].
        </p>
        <p>
         Erythropoietin has been postulated to have neuroprotective effects. However, two randomized clinical trials have not demonstrated a benefit in patients with TBI [
         <a href="#rid236">
          236,237
         </a>
         ]. In the larger study of 606 patients with TBI, neurologic outcome at six months was not improved, while mortality was nonsignificantly lower (11 versus 16 percent) in patients who received erythropoietin [
         <a href="#rid237">
          237
         </a>
         ]. A hemoglobin transfusion of 10 g/dL did not result in improved functional outcomes at six months as compared with the usual threshold of 7 g/dL in one trial [
         <a href="#rid236">
          236
         </a>
         ].
        </p>
        <p>
         Other agents being investigated include magnesium [
         <a href="#rid238">
          238
         </a>
         ], hyperbaric oxygen [
         <a href="#rid239">
          239
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         [
         <a href="#rid240">
          240
         </a>
         ], among others [
         <a href="#rid241">
          241
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3569975908">
         <span class="h2">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of glucocorticoid therapy following head trauma was found to be harmful in a large trial of patients with moderate to severe TBI [
         <a href="#rid242">
          242
         </a>
         ]. More than 10,000 patients were randomly assigned to treatment with
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         or to placebo within eight hours of presentation. Patients treated with glucocorticoids had increased mortality at two weeks (21 versus 18 percent; relative risk [RR] 1.18) and at six months (26 versus 22 percent; relative risk [RR] 1.15) [
         <a href="#rid243">
          243
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h1">
          PROGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H1912577271">
         <span class="h2">
          Outcomes
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe TBI
         </strong>
         – Cohort studies have suggested that patients with severe head injury (Glasgow Coma Scale [GCS] score ≤8) have approximately a 30 percent risk of death. At least one cohort study found that survivors of TBI continue to have a substantially increased risk of mortality for at least 13 years after the trauma [
         <a href="#rid244">
          244
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Multiple studies indicate, however, that significant proportions (30 to 65 percent) of patients with severe TBI will regain an independence, and that functional recovery following severe TBI can occur very slowly, extending beyond even 6 to 12 months [
         <a href="#rid245">
          245-253
         </a>
         ]. In one Australian study, one-quarter of patients who were severely disabled or vegetative at six months following decompressive craniectomy for TBI improved to a state of moderate disability or better by 18 months [
         <a href="#rid254">
          254
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Approximately 5 to 15 percent of patients with severe TBI are discharged from acute care in a vegetative state [
         <a href="#rid255">
          255-257
         </a>
         ]. Only half of these patients regain consciousness over the next year, and virtually all of these patients remain severely disabled. Outcomes are somewhat better for those in minimally conscious state. The persistent vegetative and minimally conscious states are described separately. The use of prognostic indicators for these outcomes is better defined for hypoxic-ischemic brain injury than for TBI [
         <a href="#rid258">
          258
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A randomized trial of
         <a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">
          amantadine
         </a>
         (starting at 100 mg twice daily) in 184 patients admitted to inpatient rehabilitation in a vegetative or minimally conscious state after severe TBI found that amantadine treatment was associated with accelerated recovery during the four-week active treatment phase [
         <a href="#rid259">
          259
         </a>
         ]. Rates of improvement subsequently slowed after treatment withdrawal in the amantadine group, and at week 6, disability scores in the two groups were similar. Further study is needed to determine a benefit for amantadine on long-term prognosis and its role in the treatment of patients with severe TBI. The mechanism of action for putative beneficial effect of amantadine is unclear; it is speculated that antagonism of N-methyl-D-aspartate and/or indirect agonism of dopamine may be involved.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Moderate TBI
         </strong>
         – The prognosis of patients with moderate TBI is less well studied but is not uniformly benign: mortality is approximately 15 percent, cognitive sequelae may occur in over half, and only approximately 20 percent return to their baseline level of functioning [
         <a href="#rid7">
          7,8,260-263
         </a>
         ]. Among patients with moderate TBI, pretrauma, educational attainment is associated with increased odds of disability-free recovery [
         <a href="#rid264">
          264
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2621254678">
         <span class="h2">
          Individual risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Outcome from severe head injury is dependent on a range of factors including baseline patient characteristics, severity of TBI, and the occurrence of medical complications and secondary brain insults. While many individual negative outcome predictors have been identified, each is associated with a significantly high false-positive rate and must not be used in isolation to estimate a prognosis.
        </p>
        <p>
         Identified risk factors include [
         <a href="#rid25">
          25,28,29,31,120,140,232,256,265-273
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         GCS score at presentation (especially the GCS motor score)  (
         <a class="graphic graphic_table graphicRef81854" href="/z/d/graphic/81854.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Full Outline of UnResponsiveness (FOUR) score  (
         <a class="graphic graphic_table graphicRef62673" href="/z/d/graphic/62673.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of severe CT abnormalities (high-grade subarachnoid hemorrhage, cisternal effacement, midline shift, leukoaraiosis)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pupillary function
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Associated extracranial injuries and complications
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypotension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypoxemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pyrexia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated intracranial pressure (ICP)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced cerebral perfusion pressure (CPP)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bleeding diathesis (low platelet count, abnormal coagulation parameters)
        </p>
        <p>
        </p>
        <p>
         Magnetic resonance imaging (MRI) has also been studied as a prognostic tool following TBI [
         <a href="#rid274">
          274-277
         </a>
         ]; diffuse axonal injury (DAI) and brainstem injury on MRI may predict poor long-term functional outcomes [
         <a href="#rid278">
          278,279
         </a>
         ]. However, favorable outcomes may occur despite the presence of lesions on MRI traditionally thought to portend a poor prognosis [
         <a href="#rid280">
          280
         </a>
         ], and MRI should not be used in isolation to guide prognostication following severe TBI.
        </p>
        <p>
         Other studies are evaluating the potential of biomarkers, such as the levels of S-100β protein, neuron-specific enolase, and α-synuclein in the blood and/or cerebrospinal fluid (CSF), to predict neurologic outcome [
         <a href="#rid281">
          281-283
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1758707961">
         <span class="h2">
          Outcome prediction models
         </span>
         <span class="headingEndMark">
          —
         </span>
         Outcome prediction models derived from large datasets, incorporating multiple predictors, have been developed and have undergone external validation [
         <a href="#rid269">
          269,284-286
         </a>
         ]. However, it is important to recognize that all outcome prediction models in neurologic injury are prone to confounding by self-fulfilling prophecies (where the presence of variables widely considered to be predictors of poor outcome lead to the delivery of an unfavorable prognosis to the family with consequent withdrawal of life support) within the datasets of patients used to develop and validate the model. A group of investigators in Sweden has described an overestimation of both mortality and poor outcomes in patients managed aggressively with an ICP-targeted treatment protocol [
         <a href="#rid287">
          287,288
         </a>
         ].
        </p>
        <p>
         Therefore, except in the most extreme cases, a trial of early aggressive neurosurgical and neurocritical care management, including surgical removal of evacuable lesions and ICP monitoring, should be undertaken in patients with severe TBI.
        </p>
        <p>
         The two most widely used publicly available prediction models are the International Mission for Prognosis and Analysis of Clinical Trials in TBI (IMPACT) and Corticosteroid Randomisation After Significant Head Injury (CRASH) models:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.crash2.lshtm.ac.uk%2FRisk+calculator%2Findex.html&amp;token=8WmZyxtCPDhnIAxHBR5GfIBprYMELnHqqPD1cim47062bVb8CcXZcosTPQdGqHAi9kenm8qSI7Rf%2B2j1vLjdYQ%3D%3D&amp;TOPIC_ID=4826" target="_blank">
          CRASH prediction model
         </a>
         was derived from the large international clinical trial of glucocorticoids in TBI with 10,008 subjects from high-, middle-, and low-income countries [
         <a href="#rid289">
          289
         </a>
         ]. Variables in this model include country, age, GCS, pupillary reactivity, the presence of significant extracranial injury, and specific findings on CT.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.tbi-impact.org%2F%3Fp%3Dimpact%2Fcalc&amp;token=B5m96R2F3UtHRqjLPKHFj3833kb4yikfNs5e3J4zNdABo3zw8BXZmxiS7MBe7hpF&amp;TOPIC_ID=4826" target="_blank">
          IMPACT model
         </a>
         was developed using data from 8509 patients in 11 studies [
         <a href="#rid290">
          290
         </a>
         ]. The variables in this model include age, GCS motor score, and pupillary reactivity as core clinical variables, as well as the occurrence of hypoxia and hypotension, the Marshall CT grade  (
         <a class="graphic graphic_table graphicRef67172" href="/z/d/graphic/67172.html" rel="external">
          table 5
         </a>
         ) plus other CT findings, and glucose and hemoglobin levels.
        </p>
        <p>
        </p>
        <p>
         These models have been validated in large cohorts of patients, and may have more limited applicability to individual prognostication.
        </p>
        <p class="headingAnchor" id="H1162967814">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116408.html" rel="external">
          "Society guideline links: Increased intracranial pressure and moderate-to-severe traumatic brain injury"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H110297514">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/17111.html" rel="external">
          "Patient education: Head injury in adults (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definitions and triage
         </strong>
         – Patients with moderate (Glasgow Coma Scale [GCS] score 9 through 13) and severe (GCS score &lt;9) traumatic brain injury (TBI) are most optimally managed in a specialized neurotrauma center with neurosurgical and neurocritical care support and the use of guidelines-based protocols.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prehospital care
         </strong>
         – Prevention of hypoxia (PaO
         <sub>
          2
         </sub>
         &lt;60 mmHg) and hypotension (systolic blood pressure [BP] &lt;100 mmHg) are priorities in the management of patients with moderate or severe TBI beginning during their prehospital care. (See
         <a class="local">
          'Initial evaluation and treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Emergency department care
         </strong>
         – Patients with TBI and GCS score &lt;9 should undergo endotracheal intubation in the emergency department (ED), if not before. Specific considerations exist when performing endotracheal intubation in patients with suspected elevation in intracranial pressure (ICP). Multiple factors must be considered when making decisions about prehospital intubation of patients with moderate or severe TBI. (See
         <a class="local">
          'Prehospital'
         </a>
         above and
         <a class="local">
          'Emergency department'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         ED evaluation should include frequent clinical neurologic assessments and a CT scan of the head. (See
         <a class="local">
          'Emergency department'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antifibrinolytic therapy
         </strong>
         – For patients with moderate TBI presenting to the ED within three hours of injury, we recommend immediate administration of
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Tranexamic acid (1 g infused over 10 minutes, followed by an intravenous infusion of 1 g over eight hours) is associated with reduced mortality in patients with moderate TBI. Prehospital administration of tranexamic acid is not recommended.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The use of
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         in patients can be considered in other patient groups; however, the impact on mortality is uncertain in these patients. (See
         <a class="local">
          'Antifibrinolytic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ventilation
         </strong>
         – Hyperventilation should be avoided in the first 24 to 48 hours and should not exceed PaCO
         <sub>
          2
         </sub>
         &lt;30 mmHg except as a temporizing measure in a patient with impending cerebral herniation. Positive end-expiratory pressure (PEEP) up to 15 to 20 cm H
         <sub>
          2
         </sub>
         O may be utilized to manage acute respiratory distress syndrome (ARDS) following TBI while ICP is monitored. (See
         <a class="local">
          'Ventilation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgery
         </strong>
         – Surgical evacuation of epidural, subdural, and intracerebral hematomas should be decided based upon hematoma volume and associated mass effect, in conjunction with the patient's neurologic status. (See
         <a class="local">
          'Surgical treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intracranial pressure management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Impending herniation
         </strong>
         – Impending cerebral herniation is an emergency and manifests with unilateral or bilateral fixed and dilated pupils, decorticate or decerebrate posturing, respiratory depression, and the "Cushing triad" of hypertension, bradycardia, and irregular respiration.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         When impending herniation due to elevated ICP is suspected, we recommend empiric interventions including endotracheal intubation, head of bed (HOB) elevation, and hyperventilation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We also recommend bolus dose of 23.4 percent sodium chloride or
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         pending the results of the CT and measurement of ICP (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ). (See
         <a class="local">
          'Patients with impending cerebral herniation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          ICP monitoring and management
         </strong>
         – For patients with severe TBI and an abnormal CT scan showing evidence of mass effect from lesions such as hematomas, contusions, or swelling, we suggest ventriculostomy and ICP monitoring along with treatment of elevated ICP to target pressures below 22 mmHg (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'ICP and CPP monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Appropriate first measures include removal of cerebrospinal fluid (CSF) through the ventriculostomy, HOB elevation, and analgesia and sedation, followed by osmotic therapy with either hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         or
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         . (See
         <a class="local">
          'Initial (baseline) treatment'
         </a>
         above and
         <a class="local">
          'Cerebrospinal fluid drainage'
         </a>
         above and
         <a class="local">
          'Sedation and analgesia'
         </a>
         above and
         <a class="local">
          'Osmotic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Refractory ICP elevation
         </strong>
         – For patients with elevated ICP refractory to initial therapy, options include decompressive craniectomy, barbiturate coma, and induced hypothermia. Such patients have a poor prognosis; further interventions should be based on a risk-benefit discussion with family. (See
         <a class="local">
          'Refractory ICP elevation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fluid and hemodynamic management
         </strong>
         – We suggest using normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         rather than colloid solutions to maintain euvolemia (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other management strategies prioritize avoiding hypotension and maintaining cerebral perfusion pressure (CPP). (See
         <a class="local">
          'Hemodynamic management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seizure prevention and treatment
         </strong>
         – We recommend one-week use of antiseizure medications to prevent early seizures (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Patients with seizures should be treated to prevent recurrence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We suggest
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         for prevention and treatment of seizures (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ); other antiseizure medications (eg,
         <a class="drug drug_general" data-topicid="8480" href="/z/d/drug information/8480.html" rel="external">
          fosphenytoin
         </a>
         ) that can be provided parenterally are reasonable alternatives. (See
         <a class="local">
          'Antiseizure medications and electroencephalography monitoring'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2213.html" rel="external">
          "Posttraumatic seizures and epilepsy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other aspects of supportive care
         </strong>
         – Fever and hyperglycemia should be avoided for their potential to exacerbate secondary neurologic injury. Nutritional support to caloric goals should be achieved by day 5 from injury using enteral nutrition. Coagulopathy should be corrected to maintain an international normalized ratio (INR) &lt;1.4 and a platelet count &gt;75,000/mm
         <sup>
          3
         </sup>
         . (See
         <a class="local">
          'Temperature management'
         </a>
         above and
         <a class="local">
          'Glucose management'
         </a>
         above and
         <a class="local">
          'Nutritional support'
         </a>
         above and
         <a class="local">
          'Management of coagulopathy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Paroxysmal sympathetic hyperactivity (PSH)
         </strong>
         – PSH, characterized by episodes of hypertension, tachycardia, and other dysautonomias, may occur following TBI and correlates with severity of injury. (See
         <a class="medical medical_review" href="/z/d/html/122115.html" rel="external">
          "Paroxysmal sympathetic hyperactivity"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Venous thromboembolism (VTE) prophylaxis
         </strong>
         – We recommend mechanical thromboprophylaxis with intermittent pneumatic compression for the prevention of VTE (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). The use and timing of antithrombotic agents is individualized based upon an assessment of the competing risks of venous thrombosis and intracranial hemorrhage expansion. (See
         <a class="local">
          'Hemodynamic management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H111921336">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Nicholas Phan, MD, FRCSC, FACS, and J Claude Hemphill, III, MD, MAS, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Taylor CA, Bell JM, Breiding MJ, Xu L. Traumatic Brain Injury-Related Emergency Department Visits, Hospitalizations, and Deaths - United States, 2007 and 2013. MMWR Surveill Summ 2017; 66:1.
          </a>
         </li>
         <li class="breakAll">
          Finkelstein E, Corso P, Miller T. The Incidence and Economic Burden of Injuries in the United States, Oxford University Press, New York 2006.
         </li>
         <li class="breakAll">
          Coronado V, McGuire L, Faul M, et al. Epidemiology and public health issues. In: Brain Injury Medicine: Principles and Practice, 2nd ed, Zasler ND, Katz DI, Zafonte RD, et al (Eds), Demos Medical Publishing, New York 2012.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974; 2:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foulkes MA, Eisenberg HM, Jane JA, et al. The Traumatic Coma Data Bank: design, methods, and baseline characteristics. J Neurosurg 1991; 75:S8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kay T, Harrington DE, Adams R, et al. Definition of mild traumatic brain injury. J Head Trauma Rehabil 1993; 8:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godoy DA, Rubiano A, Rabinstein AA, et al. Moderate Traumatic Brain Injury: The Grey Zone of Neurotrauma. Neurocrit Care 2016; 25:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godoy DA, Aguilera S, Rabinstein AA. Potentially Severe (Moderate) Traumatic Brain Injury: A New Categorization Proposal. Crit Care Med 2020; 48:1851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein SC. Minor head injury: 13 is an unlucky number. J Trauma 2001; 50:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Compagnone C, d'Avella D, Servadei F, et al. Patients with moderate head injury: a prospective multicenter study of 315 patients. Neurosurgery 2009; 64:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. Introduction. J Neurotrauma 2007; 24 Suppl 1:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maas AI, Dearden M, Teasdale GM, et al. EBIC-guidelines for management of severe head injury in adults. European Brain Injury Consortium. Acta Neurochir (Wien) 1997; 139:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newcombe R, Merry G. The management of acute neurotrauma in rural and remote locations: A set of guidelines for the care of head and spinal injuries. J Clin Neurosci 1999; 6:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adelson PD, Bratton SL, Carney NA, et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 1: Introduction. Pediatr Crit Care Med 2003; 4:S2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carney N, Totten AM, O'Reilly C, et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery 2017; 80:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel HC, Bouamra O, Woodford M, et al. Trends in head injury outcome from 1989 to 2003 and the effect of neurosurgical care: an observational study. Lancet 2005; 366:1538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suarez JI, Zaidat OO, Suri MF, et al. Length of stay and mortality in neurocritically ill patients: impact of a specialized neurocritical care team. Crit Care Med 2004; 32:2311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thillai M. Neurosurgical units working beyond safe capacity. BMJ 2000; 320:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varelas PN, Conti MM, Spanaki MV, et al. The impact of a neurointensivist-led team on a semiclosed neurosciences intensive care unit. Crit Care Med 2004; 32:2191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Visca A, Faccani G, Massaro F, et al. Clinical and neuroimaging features of severely brain-injured patients treated in a neurosurgical unit compared with patients treated in peripheral non-neurosurgical hospitals. Br J Neurosurg 2006; 20:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown JB, Stassen NA, Cheng JD, et al. Trauma center designation correlates with functional independence after severe but not moderate traumatic brain injury. J Trauma 2010; 69:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tepas JJ 3rd, Pracht EE, Orban BL, Flint LM. High-volume trauma centers have better outcomes treating traumatic brain injury. J Trauma Acute Care Surg 2013; 74:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pineda JA, Leonard JR, Mazotas IG, et al. Effect of implementation of a paediatric neurocritical care programme on outcomes after severe traumatic brain injury: a retrospective cohort study. Lancet Neurol 2013; 12:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. I. Blood pressure and oxygenation. J Neurotrauma 2007; 24 Suppl 1:S7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McHugh GS, Engel DC, Butcher I, et al. Prognostic value of secondary insults in traumatic brain injury: results from the IMPACT study. J Neurotrauma 2007; 24:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silverston P. Pulse oximetry at the roadside: a study of pulse oximetry in immediate care. BMJ 1989; 298:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stocchetti N, Furlan A, Volta F. Hypoxemia and arterial hypotension at the accident scene in head injury. J Trauma 1996; 40:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chesnut RM, Marshall LF, Klauber MR, et al. The role of secondary brain injury in determining outcome from severe head injury. J Trauma 1993; 34:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manley G, Knudson MM, Morabito D, et al. Hypotension, hypoxia, and head injury: frequency, duration, and consequences. Arch Surg 2001; 136:1118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuller G, Hasler RM, Mealing N, et al. The association between admission systolic blood pressure and mortality in significant traumatic brain injury: a multi-centre cohort study. Injury 2014; 45:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrews PJ, Sleeman DH, Statham PF, et al. Predicting recovery in patients suffering from traumatic brain injury by using admission variables and physiological data: a comparison between decision tree analysis and logistic regression. J Neurosurg 2002; 97:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clifton GL, Miller ER, Choi SC, Levin HS. Fluid thresholds and outcome from severe brain injury. Crit Care Med 2002; 30:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winchell RJ, Hoyt DB. Endotracheal intubation in the field improves survival in patients with severe head injury. Trauma Research and Education Foundation of San Diego. Arch Surg 1997; 132:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudehill A, Bellander BM, Weitzberg E, et al. Outcome of traumatic brain injuries in 1,508 patients: impact of prehospital care. J Neurotrauma 2002; 19:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis DP, Peay J, Sise MJ, et al. Prehospital airway and ventilation management: a trauma score and injury severity score-based analysis. J Trauma 2010; 69:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Badjatia N, Carney N, Crocco TJ, et al. Guidelines for prehospital management of traumatic brain injury 2nd edition. Prehosp Emerg Care 2008; 12 Suppl 1:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaither JB, Spaite DW, Bobrow BJ, et al. Balancing the potential risks and benefits of out-of-hospital intubation in traumatic brain injury: the intubation/hyperventilation effect. Ann Emerg Med 2012; 60:732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Elm E, Schoettker P, Henzi I, et al. Pre-hospital tracheal intubation in patients with traumatic brain injury: systematic review of current evidence. Br J Anaesth 2009; 103:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis DP, Peay J, Sise MJ, et al. The impact of prehospital endotracheal intubation on outcome in moderate to severe traumatic brain injury. J Trauma 2005; 58:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis DP, Peay J, Serrano JA, et al. The impact of aeromedical response to patients with moderate to severe traumatic brain injury. Ann Emerg Med 2005; 46:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernard SA, Nguyen V, Cameron P, et al. Prehospital rapid sequence intubation improves functional outcome for patients with severe traumatic brain injury: a randomized controlled trial. Ann Surg 2010; 252:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper DJ, Myles PS, McDermott FT, et al. Prehospital hypertonic saline resuscitation of patients with hypotension and severe traumatic brain injury: a randomized controlled trial. JAMA 2004; 291:1350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bulger EM, May S, Brasel KJ, et al. Out-of-hospital hypertonic resuscitation following severe traumatic brain injury: a randomized controlled trial. JAMA 2010; 304:1455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowell SE, Meier EN, McKnight B, et al. Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury. JAMA 2020; 324:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wijdicks EF, Bamlet WR, Maramattom BV, et al. Validation of a new coma scale: The FOUR score. Ann Neurol 2005; 58:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNett MM, Amato S, Philippbar SA. A Comparative Study of Glasgow Coma Scale and Full Outline of Unresponsiveness Scores for Predicting Long-Term Outcome After Brain Injury. J Neurosci Nurs 2016; 48:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasprowicz M, Burzynska M, Melcer T, Kübler A. A comparison of the Full Outline of UnResponsiveness (FOUR) score and Glasgow Coma Score (GCS) in predictive modelling in traumatic brain injury. Br J Neurosurg 2016; 30:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cadena R, Shoykhet M, Ratcliff JJ. Emergency Neurological Life Support: Intracranial Hypertension and Herniation. Neurocrit Care 2017; 27:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet 2019; 394:1713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CRASH-2 Collaborators, Intracranial Bleeding Study. Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study). BMJ 2011; 343:d3795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yutthakasemsunt S, Kittiwatanagul W, Piyavechvirat P, et al. Tranexamic acid for patients with traumatic brain injury: a randomized, double-blinded, placebo-controlled trial. BMC Emerg Med 2013; 13:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zehtabchi S, Abdel Baki SG, Falzon L, Nishijima DK. Tranexamic acid for traumatic brain injury: a systematic review and meta-analysis. Am J Emerg Med 2014; 32:1503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of acute epidural hematomas. Neurosurgery 2006; 58:S7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of acute subdural hematomas. Neurosurgery 2006; 58:S16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of posterior fossa mass lesions. Neurosurgery 2006; 58:S47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of traumatic parenchymal lesions. Neurosurgery 2006; 58:S25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Surgical management of penetrating brain injury. J Trauma 2001; 51:S16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antibiotic prophylaxis for penetrating brain injury. J Trauma 2001; 51:S34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of depressed cranial fractures. Neurosurgery 2006; 58:S56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunn LT, Fitzpatrick MO, Beard D, Henry JM. Patients with a head injury who "talk and die" in the 1990s. J Trauma 2003; 54:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reilly PL, Graham DI, Adams JH, Jennett B. Patients with head injury who talk and die. Lancet 1975; 2:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Servadei F, Murray GD, Penny K, et al. The value of the "worst" computed tomographic scan in clinical studies of moderate and severe head injury. European Brain Injury Consortium. Neurosurgery 2000; 46:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang EF, Meeker M, Holland MC. Acute traumatic intraparenchymal hemorrhage: risk factors for progression in the early post-injury period. Neurosurgery 2006; 58:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oertel M, Kelly DF, McArthur D, et al. Progressive hemorrhage after head trauma: predictors and consequences of the evolving injury. J Neurosurg 2002; 96:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narayan RK, Maas AI, Servadei F, et al. Progression of traumatic intracerebral hemorrhage: a prospective observational study. J Neurotrauma 2008; 25:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas BW, Mejia VA, Maxwell RA, et al. Scheduled repeat CT scanning for traumatic brain injury remains important in assessing head injury progression. J Am Coll Surg 2010; 210:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connon FF, Namdarian B, Ee JL, et al. Do routinely repeated computed tomography scans in traumatic brain injury influence management? A prospective observational study in a level 1 trauma center. Ann Surg 2011; 254:1028.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaups KL, Davis JW, Parks SN. Routinely repeated computed tomography after blunt head trauma: does it benefit patients? J Trauma 2004; 56:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown CV, Zada G, Salim A, et al. Indications for routine repeat head computed tomography (CT) stratified by severity of traumatic brain injury. J Trauma 2007; 62:1339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang AP, Lee CW, Hsieh HJ, et al. Early parenchymal contrast extravasation predicts subsequent hemorrhage progression, clinical deterioration, and need for surgery in patients with traumatic cerebral contusion. J Trauma 2011; 71:1593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SAFE Study Investigators, Australian and New Zealand Intensive Care Society Clinical Trials Group, Australian Red Cross Blood Service, et al. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 2007; 357:874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Semler MW, Self WH, Wanderer JP, et al. Balanced Crystalloids versus Saline in Critically Ill Adults. N Engl J Med 2018; 378:829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouma GJ, Muizelaar JP. Cerebral blood flow, cerebral blood volume, and cerebrovascular reactivity after severe head injury. J Neurotrauma 1992; 9 Suppl 1:S333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouma GJ, Muizelaar JP, Bandoh K, Marmarou A. Blood pressure and intracranial pressure-volume dynamics in severe head injury: relationship with cerebral blood flow. J Neurosurg 1992; 77:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muizelaar JP, Ward JD, Marmarou A, et al. Cerebral blood flow and metabolism in severely head-injured children. Part 2: Autoregulation. J Neurosurg 1989; 71:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juul N, Morris GF, Marshall SB, Marshall LF. Intracranial hypertension and cerebral perfusion pressure: influence on neurological deterioration and outcome in severe head injury. The Executive Committee of the International Selfotel Trial. J Neurosurg 2000; 92:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosner MJ, Daughton S. Cerebral perfusion pressure management in head injury. J Trauma 1990; 30:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robertson CS, Valadka AB, Hannay HJ, et al. Prevention of secondary ischemic insults after severe head injury. Crit Care Med 1999; 27:2086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howells T, Elf K, Jones PA, et al. Pressure reactivity as a guide in the treatment of cerebral perfusion pressure in patients with brain trauma. J Neurosurg 2005; 102:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Contant CF, Valadka AB, Gopinath SP, et al. Adult respiratory distress syndrome: a complication of induced hypertension after severe head injury. J Neurosurg 2001; 95:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grände PO. The "Lund Concept" for the treatment of severe head trauma--physiological principles and clinical application. Intensive Care Med 2006; 32:1475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vandromme MJ, Melton SM, Griffin R, et al. Intubation patterns and outcomes in patients with computed tomography-verified traumatic brain injury. J Trauma 2011; 71:1615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diringer MN, Yundt K, Videen TO, et al. No reduction in cerebral metabolism as a result of early moderate hyperventilation following severe traumatic brain injury. J Neurosurg 2000; 92:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stocchetti N, Maas AI, Chieregato A, van der Plas AA. Hyperventilation in head injury: a review. Chest 2005; 127:1812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imberti R, Bellinzona G, Langer M. Cerebral tissue PO2 and SjvO2 changes during moderate hyperventilation in patients with severe traumatic brain injury. J Neurosurg 2002; 96:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coles JP, Minhas PS, Fryer TD, et al. Effect of hyperventilation on cerebral blood flow in traumatic head injury: clinical relevance and monitoring correlates. Crit Care Med 2002; 30:1950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marion DW, Puccio A, Wisniewski SR, et al. Effect of hyperventilation on extracellular concentrations of glutamate, lactate, pyruvate, and local cerebral blood flow in patients with severe traumatic brain injury. Crit Care Med 2002; 30:2619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muizelaar JP, Marmarou A, Ward JD, et al. Adverse effects of prolonged hyperventilation in patients with severe head injury: a randomized clinical trial. J Neurosurg 1991; 75:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. XIV. Hyperventilation. J Neurotrauma 2007; 24 Suppl 1:S87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boone MD, Jinadasa SP, Mueller A, et al. The Effect of Positive End-Expiratory Pressure on Intracranial Pressure and Cerebral Hemodynamics. Neurocrit Care 2017; 26:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muench E, Bauhuf C, Roth H, et al. Effects of positive end-expiratory pressure on regional cerebral blood flow, intracranial pressure, and brain tissue oxygenation. Crit Care Med 2005; 33:2367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nemer SN, Caldeira JB, Santos RG, et al. Effects of positive end-expiratory pressure on brain tissue oxygen pressure of severe traumatic brain injury patients with acute respiratory distress syndrome: A pilot study. J Crit Care 2015; 30:1263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fletcher JJ, Wilson TJ, Rajajee V, et al. Changes in Therapeutic Intensity Level Following Airway Pressure Release Ventilation in Severe Traumatic Brain Injury. J Intensive Care Med 2018; 33:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Temkin NR, Dikmen SS, Wilensky AJ, et al. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med 1990; 323:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schierhout G, Roberts I. Anti-epileptic drugs for preventing seizures following acute traumatic brain injury. Cochrane Database Syst Rev 2001; :CD000173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care 2010; 12:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Temkin NR. Risk factors for posttraumatic seizures in adults. Epilepsia 2003; 44 Suppl 10:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frey LC. Epidemiology of posttraumatic epilepsy: a critical review. Epilepsia 2003; 44 Suppl 10:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vespa PM, Nuwer MR, Nenov V, et al. Increased incidence and impact of nonconvulsive and convulsive seizures after traumatic brain injury as detected by continuous electroencephalographic monitoring. J Neurosurg 1999; 91:750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ronne-Engstrom E, Winkler T. Continuous EEG monitoring in patients with traumatic brain injury reveals a high incidence of epileptiform activity. Acta Neurol Scand 2006; 114:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimmermann LL, Diaz-Arrastia R, Vespa PM. Seizures and the Role of Anticonvulsants After Traumatic Brain Injury. Neurosurg Clin N Am 2016; 27:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naidech AM, Kreiter KT, Janjua N, et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke 2005; 36:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inaba K, Menaker J, Branco BC, et al. A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis. J Trauma Acute Care Surg 2013; 74:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu JC, Shen J, Shao WZ, et al. The safety and efficacy of levetiracetam versus phenytoin for seizure prophylaxis after traumatic brain injury: A systematic review and meta-analysis. Brain Inj 2016; 30:1054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. V. Deep vein thrombosis prophylaxis. J Neurotrauma 2007; 24 Suppl 1:S32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reiff DA, Haricharan RN, Bullington NM, et al. Traumatic brain injury is associated with the development of deep vein thrombosis independent of pharmacological prophylaxis. J Trauma 2009; 66:1436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norwood SH, Berne JD, Rowe SA, et al. Early venous thromboembolism prophylaxis with enoxaparin in patients with blunt traumatic brain injury. J Trauma 2008; 65:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norwood SH, McAuley CE, Berne JD, et al. Prospective evaluation of the safety of enoxaparin prophylaxis for venous thromboembolism in patients with intracranial hemorrhagic injuries. Arch Surg 2002; 137:696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salottolo K, Offner P, Levy AS, et al. Interrupted pharmocologic thromboprophylaxis increases venous thromboembolism in traumatic brain injury. J Trauma 2011; 70:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koehler DM, Shipman J, Davidson MA, Guillamondegui O. Is early venous thromboembolism prophylaxis safe in trauma patients with intracranial hemorrhage. J Trauma 2011; 70:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scudday T, Brasel K, Webb T, et al. Safety and efficacy of prophylactic anticoagulation in patients with traumatic brain injury. J Am Coll Surg 2011; 213:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saadeh Y, Gohil K, Bill C, et al. Chemical venous thromboembolic prophylaxis is safe and effective for patients with traumatic brain injury when started 24 hours after the absence of hemorrhage progression on head CT. J Trauma Acute Care Surg 2012; 73:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwiatt ME, Patel MS, Ross SE, et al. Is low-molecular-weight heparin safe for venous thromboembolism prophylaxis in patients with traumatic brain injury? A Western Trauma Association multicenter study. J Trauma Acute Care Surg 2012; 73:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phelan HA, Wolf SE, Norwood SH, et al. A randomized, double-blinded, placebo-controlled pilot trial of anticoagulation in low-risk traumatic brain injury: The Delayed Versus Early Enoxaparin Prophylaxis I (DEEP I) study. J Trauma Acute Care Surg 2012; 73:1434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Margolick J, Dandurand C, Duncan K, et al. A Systematic Review of the Risks and Benefits of Venous Thromboembolism Prophylaxis in Traumatic Brain Injury. Can J Neurol Sci 2018; 45:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harhangi BS, Kompanje EJ, Leebeek FW, Maas AI. Coagulation disorders after traumatic brain injury. Acta Neurochir (Wien) 2008; 150:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allard CB, Scarpelini S, Rhind SG, et al. Abnormal coagulation tests are associated with progression of traumatic intracranial hemorrhage. J Trauma 2009; 67:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wafaisade A, Lefering R, Tjardes T, et al. Acute coagulopathy in isolated blunt traumatic brain injury. Neurocrit Care 2010; 12:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein SC, Young GS, Talucci RC, et al. Delayed brain injury after head trauma: significance of coagulopathy. Neurosurgery 1992; 30:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray GD, Butcher I, McHugh GS, et al. Multivariable prognostic analysis in traumatic brain injury: results from the IMPACT study. J Neurotrauma 2007; 24:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Oliveira Manoel AL, Neto AC, Veigas PV, Rizoli S. Traumatic brain injury associated coagulopathy. Neurocrit Care 2015; 22:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zehtabchi S, Soghoian S, Liu Y, et al. The association of coagulopathy and traumatic brain injury in patients with isolated head injury. Resuscitation 2008; 76:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edavettal M, Vellucci A, Rogers FB. Traumatic brain injury is not associated with coagulopathy out of proportion to injury in other body regions. J Trauma Acute Care Surg 2014; 77:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joseph B, Pandit V, Meyer D, et al. The significance of platelet count in traumatic brain injury patients on antiplatelet therapy. J Trauma Acute Care Surg 2014; 77:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishijima DK, Zehtabchi S, Berrong J, Legome E. Utility of platelet transfusion in adult patients with traumatic intracranial hemorrhage and preinjury antiplatelet use: a systematic review. J Trauma Acute Care Surg 2012; 72:1658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perel P, Roberts I, Shakur H, et al. Haemostatic drugs for traumatic brain injury. Cochrane Database Syst Rev 2010; :CD007877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narayan RK, Maas AI, Marshall LF, et al. Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial. Neurosurgery 2008; 62:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rovlias A, Kotsou S. The influence of hyperglycemia on neurological outcome in patients with severe head injury. Neurosurgery 2000; 46:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeremitsky E, Omert LA, Dunham CM, et al. The impact of hyperglycemia on patients with severe brain injury. J Trauma 2005; 58:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam AM, Winn HR, Cullen BF, Sundling N. Hyperglycemia and neurological outcome in patients with head injury. J Neurosurg 1991; 75:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oddo M, Schmidt JM, Carrera E, et al. Impact of tight glycemic control on cerebral glucose metabolism after severe brain injury: a microdialysis study. Crit Care Med 2008; 36:3233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puccio AM, Fischer MR, Jankowitz BT, et al. Induced normothermia attenuates intracranial hypertension and reduces fever burden after severe traumatic brain injury. Neurocrit Care 2009; 11:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oddo M, Frangos S, Maloney-Wilensky E, et al. Effect of shivering on brain tissue oxygenation during induced normothermia in patients with severe brain injury. Neurocrit Care 2010; 12:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konstantinidis A, Inaba K, Dubose J, et al. The impact of nontherapeutic hypothermia on outcomes after severe traumatic brain injury. J Trauma 2011; 71:1627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Acosta-Escribano J, Fernández-Vivas M, Grau Carmona T, et al. Gastric versus transpyloric feeding in severe traumatic brain injury: a prospective, randomized trial. Intensive Care Med 2010; 36:1532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lepelletier D, Roquilly A, Demeure dit latte D, et al. Retrospective analysis of the risk factors and pathogens associated with early-onset ventilator-associated pneumonia in surgical-ICU head-trauma patients. J Neurosurg Anesthesiol 2010; 22:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Härtl R, Gerber LM, Ni Q, Ghajar J. Effect of early nutrition on deaths due to severe traumatic brain injury. J Neurosurg 2008; 109:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chourdakis M, Kraus MM, Tzellos T, et al. Effect of early compared with delayed enteral nutrition on endocrine function in patients with traumatic brain injury: an open-labeled randomized trial. JPEN J Parenter Enteral Nutr 2012; 36:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marmarou A, Anderson L, Ward J, et al. Impact of ICP instability and hypotension on outcome in patients with severe head trauma. J Neurosurg 1991; 75:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schreiber MA, Aoki N, Scott BG, Beck JR. Determinants of mortality in patients with severe blunt head injury. Arch Surg 2002; 137:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Badri S, Chen J, Barber J, et al. Mortality and long-term functional outcome associated with intracranial pressure after traumatic brain injury. Intensive Care Med 2012; 38:1800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qureshi AI, Geocadin RG, Suarez JI, Ulatowski JA. Long-term outcome after medical reversal of transtentorial herniation in patients with supratentorial mass lesions. Crit Care Med 2000; 28:1556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koenig MA, Bryan M, Lewin JL 3rd, et al. Reversal of transtentorial herniation with hypertonic saline. Neurology 2008; 70:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faiver L, Hensler D, Rush SC, et al. Safety and Efficacy of 23.4% Sodium Chloride Administered via Peripheral Venous Access for the Treatment of Cerebral Herniation and Intracranial Pressure Elevation. Neurocrit Care 2021; 35:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. VI. Indications for intracranial pressure monitoring. J Neurotrauma 2007; 24 Suppl 1:S37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chesnut RM, Temkin N, Carney N, et al. A trial of intracranial-pressure monitoring in traumatic brain injury. N Engl J Med 2012; 367:2471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agrawal D, Raghavendran K, Schaubel DE, et al. A Propensity Score Analysis of the Impact of Invasive Intracranial Pressure Monitoring on Outcomes after Severe Traumatic Brain Injury. J Neurotrauma 2016; 33:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joseph M. Intracranial pressure monitoring in a resource-constrained environment: a technical note. Neurol India 2003; 51:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sorrentino E, Diedler J, Kasprowicz M, et al. Critical thresholds for cerebrovascular reactivity after traumatic brain injury. Neurocrit Care 2012; 16:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lundberg N, Troupp H, Lorin H. Continuous recording of the ventricular-fluid pressure in patients with severe acute traumatic brain injury. A preliminary report. J Neurosurg 1965; 22:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. II. Hyperosmolar therapy. J Neurotrauma 2007; 24 Suppl 1:S14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biersteker HA, Andriessen TM, Horn J, et al. Factors influencing intracranial pressure monitoring guideline compliance and outcome after severe traumatic brain injury. Crit Care Med 2012; 40:1914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farahvar A, Gerber LM, Chiu YL, et al. Increased mortality in patients with severe traumatic brain injury treated without intracranial pressure monitoring. J Neurosurg 2012; 117:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan MN, Shallwani H, Khan MU, Shamim MS. Noninvasive monitoring intracranial pressure - A review of available modalities. Surg Neurol Int 2017; 8:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karakitsos D, Soldatos T, Gouliamos A, et al. Transorbital sonographic monitoring of optic nerve diameter in patients with severe brain injury. Transplant Proc 2006; 38:3700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajajee V, Vanaman M, Fletcher JJ, Jacobs TL. Optic nerve ultrasound for the detection of raised intracranial pressure. Neurocrit Care 2011; 15:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robba C, Santori G, Czosnyka M, et al. Optic nerve sheath diameter measured sonographically as non-invasive estimator of intracranial pressure: a systematic review and meta-analysis. Intensive Care Med 2018; 44:1284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agrawal D, Raghavendran K, Zhao L, Rajajee V. A Prospective Study of Optic Nerve Ultrasound for the Detection of Elevated Intracranial Pressure in Severe Traumatic Brain Injury. Crit Care Med 2020; 48:e1278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cardim D, Robba C, Bohdanowicz M, et al. Non-invasive Monitoring of Intracranial Pressure Using Transcranial Doppler Ultrasonography: Is It Possible? Neurocrit Care 2016; 25:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rasulo FA, Bertuetti R, Robba C, et al. The accuracy of transcranial Doppler in excluding intracranial hypertension following acute brain injury: a multicenter prospective pilot study. Crit Care 2017; 21:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robba C, Cardim D, Tajsic T, et al. Ultrasound non-invasive measurement of intracranial pressure in neurointensive care: A prospective observational study. PLoS Med 2017; 14:e1002356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nwachuku EL, Puccio AM, Fetzick A, et al. Intermittent versus continuous cerebrospinal fluid drainage management in adult severe traumatic brain injury: assessment of intracranial pressure burden. Neurocrit Care 2014; 20:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med 2018; 46:e825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajajee V, Riggs B, Seder DB. Emergency Neurological Life Support: Airway, Ventilation, and Sedation. Neurocrit Care 2017; 27:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skoglund K, Enblad P, Marklund N. Effects of the neurological wake-up test on intracranial pressure and cerebral perfusion pressure in brain-injured patients. Neurocrit Care 2009; 11:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly DF, Goodale DB, Williams J, et al. Propofol in the treatment of moderate and severe head injury: a randomized, prospective double-blinded pilot trial. J Neurosurg 1999; 90:1042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossaint J, Rossaint R, Weis J, et al. Propofol: neuroprotection in an in vitro model of traumatic brain injury. Crit Care 2009; 13:R61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith H, Sinson G, Varelas P. Vasopressors and propofol infusion syndrome in severe head trauma. Neurocrit Care 2009; 10:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hinson HE, Stein D, Sheth KN. Hypertonic saline and mannitol therapy in critical care neurology. J Intensive Care Med 2013; 28:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boone MD, Oren-Grinberg A, Robinson TM, et al. Mannitol or hypertonic saline in the setting of traumatic brain injury: What have we learned? Surg Neurol Int 2015; 6:177.
          </a>
         </li>
         <li class="breakAll">
          Diringer MN. The Evolution of the Clinical Use of Osmotic Therapy in the Treatment of Cerebral Edema. In: Brain Edema XVI: Translate Basic Science into Clinical Practice, Applegate RL, Chen G, Feng H, Zhang JH (Eds), Springer International Publishing, 2016. p.3.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Battison C, Andrews PJ, Graham C, Petty T. Randomized, controlled trial on the effect of a 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury. Crit Care Med 2005; 33:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vialet R, Albanèse J, Thomachot L, et al. Isovolume hypertonic solutes (sodium chloride or mannitol) in the treatment of refractory posttraumatic intracranial hypertension: 2 mL/kg 7.5% saline is more effective than 2 mL/kg 20% mannitol. Crit Care Med 2003; 31:1683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alnemari AM, Krafcik BM, Mansour TR, Gaudin D. A Comparison of Pharmacologic Therapeutic Agents Used for the Reduction of Intracranial Pressure After Traumatic Brain Injury. World Neurosurg 2017; 106:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger-Pelleiter E, Émond M, Lauzier F, et al. Hypertonic saline in severe traumatic brain injury: a systematic review and meta-analysis of randomized controlled trials. CJEM 2016; 18:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burgess S, Abu-Laban RB, Slavik RS, et al. A Systematic Review of Randomized Controlled Trials Comparing Hypertonic Sodium Solutions and Mannitol for Traumatic Brain Injury: Implications for Emergency Department Management. Ann Pharmacother 2016; 50:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mangat HS, Chiu YL, Gerber LM, et al. Hypertonic saline reduces cumulative and daily intracranial pressure burdens after severe traumatic brain injury. J Neurosurg 2015; 122:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cottenceau V, Masson F, Mahamid E, et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. J Neurotrauma 2011; 28:2003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li M, Chen T, Chen SD, et al. Comparison of equimolar doses of mannitol and hypertonic saline for the treatment of elevated intracranial pressure after traumatic brain injury: a systematic review and meta-analysis. Medicine (Baltimore) 2015; 94:e736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oddo M, Levine JM, Frangos S, et al. Effect of mannitol and hypertonic saline on cerebral oxygenation in patients with severe traumatic brain injury and refractory intracranial hypertension. J Neurol Neurosurg Psychiatry 2009; 80:916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakellaridis N, Pavlou E, Karatzas S, et al. Comparison of mannitol and hypertonic saline in the treatment of severe brain injuries. J Neurosurg 2011; 114:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shackford SR, Bourguignon PR, Wald SL, et al. Hypertonic saline resuscitation of patients with head injury: a prospective, randomized clinical trial. J Trauma 1998; 44:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ware ML, Nemani VM, Meeker M, et al. Effects of 23.4% sodium chloride solution in reducing intracranial pressure in patients with traumatic brain injury: a preliminary study. Neurosurgery 2005; 57:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loftus TJ, Efron PA, Bala TM, et al. Hypertonic saline resuscitation after emergent laparotomy and temporary abdominal closure. J Trauma Acute Care Surg 2018; 84:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James HE. Methodology for the control of intracranial pressure with hypertonic mannitol. Acta Neurochir (Wien) 1980; 51:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGraw CP, Howard G. Effect of mannitol on increased intracranial pressure. Neurosurgery 1983; 13:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muizelaar JP, Wei EP, Kontos HA, Becker DP. Mannitol causes compensatory cerebral vasoconstriction and vasodilation in response to blood viscosity changes. J Neurosurg 1983; 59:822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakowitz OW, Stover JF, Sarrafzadeh AS, et al. Effects of mannitol bolus administration on intracranial pressure, cerebral extracellular metabolites, and tissue oxygenation in severely head-injured patients. J Trauma 2007; 62:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ropper AH. Hyperosmolar therapy for raised intracranial pressure. N Engl J Med 2012; 367:746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sankar T, Assina R, Karis JP, et al. Neurosurgical implications of mannitol accumulation within a meningioma and its peritumoral region demonstrated by magnetic resonance spectroscopy: case report. J Neurosurg 2008; 108:1010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palma L, Bruni G, Fiaschi AI, Mariottini A. Passage of mannitol into the brain around gliomas: a potential cause of rebound phenomenon. A study on 21 patients. J Neurosurg Sci 2006; 50:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolmodin L, Sekhon MS, Henderson WR, et al. Hypernatremia in patients with severe traumatic brain injury: a systematic review. Ann Intensive Care 2013; 3:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawryluk GWJ, Rubiano AM, Totten AM, et al. Guidelines for the Management of Severe Traumatic Brain Injury: 2020 Update of the Decompressive Craniectomy Recommendations. Neurosurgery 2020; 87:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolias AG, Kirkpatrick PJ, Hutchinson PJ. Decompressive craniectomy: past, present and future. Nat Rev Neurol 2013; 9:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith M. Refractory Intracranial Hypertension: The Role of Decompressive Craniectomy. Anesth Analg 2017; 125:1999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qiu W, Guo C, Shen H, et al. Effects of unilateral decompressive craniectomy on patients with unilateral acute post-traumatic brain swelling after severe traumatic brain injury. Crit Care 2009; 13:R185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang JY, Xu W, Li WP, et al. Efficacy of standard trauma craniectomy for refractory intracranial hypertension with severe traumatic brain injury: a multicenter, prospective, randomized controlled study. J Neurotrauma 2005; 22:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper DJ, Rosenfeld JV, Murray L, et al. Decompressive craniectomy in diffuse traumatic brain injury. N Engl J Med 2011; 364:1493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Servadei F. Clinical value of decompressive craniectomy. N Engl J Med 2011; 364:1558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutchinson PJ, Kolias AG, Timofeev IS, et al. Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension. N Engl J Med 2016; 375:1119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts I, Sydenham E. Barbiturates for acute traumatic brain injury. Cochrane Database Syst Rev 2012; 12:CD000033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. XI. Anesthetics, analgesics, and sedatives. J Neurotrauma 2007; 24 Suppl 1:S71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamele M, Stockmann C, Cirulis M, et al. Ventilator-Associated Pneumonia in Pediatric Traumatic Brain Injury. J Neurotrauma 2016; 33:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golden TR, Solnicky V, Wadeea R, Ghazala S. Pentobarbital-induced lactic acidosis following status epilepticus barbiturate coma. BMJ Case Rep 2018; 2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller MA, Forni A, Yogaratnam D. Propylene glycol-induced lactic acidosis in a patient receiving continuous infusion pentobarbital. Ann Pharmacother 2008; 42:1502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clifton GL, Miller ER, Choi SC, et al. Lack of effect of induction of hypothermia after acute brain injury. N Engl J Med 2001; 344:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadaka F, Veremakis C. Therapeutic hypothermia for the management of intracranial hypertension in severe traumatic brain injury: a systematic review. Brain Inj 2012; 26:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. III. Prophylactic hypothermia. J Neurotrauma 2007; 24 Suppl 1:S21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adelson PD. Hypothermia following pediatric traumatic brain injury. J Neurotrauma 2009; 26:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sydenham E, Roberts I, Alderson P. Hypothermia for traumatic head injury. Cochrane Database Syst Rev 2009; :CD001048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis SR, Evans DJ, Butler AR, et al. Hypothermia for traumatic brain injury. Cochrane Database Syst Rev 2017; 9:CD001048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIntyre LA, Fergusson DA, Hébert PC, et al. Prolonged therapeutic hypothermia after traumatic brain injury in adults: a systematic review. JAMA 2003; 289:2992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henderson WR, Dhingra VK, Chittock DR, et al. Hypothermia in the management of traumatic brain injury. A systematic review and meta-analysis. Intensive Care Med 2003; 29:1637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris OA, Colford JM Jr, Good MC, Matz PG. The role of hypothermia in the management of severe brain injury: a meta-analysis. Arch Neurol 2002; 59:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Georgiou AP, Manara AR. Role of therapeutic hypothermia in improving outcome after traumatic brain injury: a systematic review. Br J Anaesth 2013; 110:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clifton GL, Valadka A, Zygun D, et al. Very early hypothermia induction in patients with severe brain injury (the National Acute Brain Injury Study: Hypothermia II): a randomised trial. Lancet Neurol 2011; 10:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrews PJ, Sinclair HL, Rodriguez A, et al. Hypothermia for Intracranial Hypertension after Traumatic Brain Injury. N Engl J Med 2015; 373:2403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutchison JS, Ward RE, Lacroix J, et al. Hypothermia therapy after traumatic brain injury in children. N Engl J Med 2008; 358:2447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adelson PD, Wisniewski SR, Beca J, et al. Comparison of hypothermia and normothermia after severe traumatic brain injury in children (Cool Kids): a phase 3, randomised controlled trial. Lancet Neurol 2013; 12:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cruz J. The first decade of continuous monitoring of jugular bulb oxyhemoglobinsaturation: management strategies and clinical outcome. Crit Care Med 1998; 26:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White H, Baker A. Continuous jugular venous oximetry in the neurointensive care unit--a brief review. Can J Anaesth 2002; 49:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gopinath SP, Robertson CS, Contant CF, et al. Jugular venous desaturation and outcome after head injury. J Neurol Neurosurg Psychiatry 1994; 57:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maloney-Wilensky E, Gracias V, Itkin A, et al. Brain tissue oxygen and outcome after severe traumatic brain injury: a systematic review. Crit Care Med 2009; 37:2057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. X. Brain oxygen monitoring and thresholds. J Neurotrauma 2007; 24 Suppl 1:S65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiotta AM, Stiefel MF, Gracias VH, et al. Brain tissue oxygen-directed management and outcome in patients with severe traumatic brain injury. J Neurosurg 2010; 113:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narotam PK, Morrison JF, Nathoo N. Brain tissue oxygen monitoring in traumatic brain injury and major trauma: outcome analysis of a brain tissue oxygen-directed therapy. J Neurosurg 2009; 111:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okonkwo DO, Shutter LA, Moore C, et al. Brain Oxygen Optimization in Severe Traumatic Brain Injury Phase-II: A Phase II Randomized Trial. Crit Care Med 2017; 45:1907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodman JC, Robertson CS. Microdialysis: is it ready for prime time? Curr Opin Crit Care 2009; 15:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Lima Oliveira M, Kairalla AC, Fonoff ET, et al. Cerebral microdialysis in traumatic brain injury and subarachnoid hemorrhage: state of the art. Neurocrit Care 2014; 21:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zweifel C, Lavinio A, Steiner LA, et al. Continuous monitoring of cerebrovascular pressure reactivity in patients with head injury. Neurosurg Focus 2008; 25:E2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazaridis C, DeSantis SM, Smielewski P, et al. Patient-specific thresholds of intracranial pressure in severe traumatic brain injury. J Neurosurg 2014; 120:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maas AI, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol 2008; 7:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skolnick BE, Maas AI, Narayan RK, et al. A clinical trial of progesterone for severe traumatic brain injury. N Engl J Med 2014; 371:2467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright DW, Yeatts SD, Silbergleit R, et al. Very early administration of progesterone for acute traumatic brain injury. N Engl J Med 2014; 371:2457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zafonte RD, Bagiella E, Ansel BM, et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA 2012; 308:1993.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robertson CS, Hannay HJ, Yamal JM, et al. Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial. JAMA 2014; 312:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nichol A, French C, Little L, et al. Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial. Lancet 2015; 386:2499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arango MF, Bainbridge D. Magnesium for acute traumatic brain injury. Cochrane Database Syst Rev 2008; :CD005400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennett MH, Trytko B, Jonker B. Hyperbaric oxygen therapy for the adjunctive treatment of traumatic brain injury. Cochrane Database Syst Rev 2012; 12:CD004609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazzeo AT, Brophy GM, Gilman CB, et al. Safety and tolerability of cyclosporin a in severe traumatic brain injury patients: results from a prospective randomized trial. J Neurotrauma 2009; 26:2195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiong Y, Mahmood A, Chopp M. Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs 2009; 14:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts I, Yates D, Sandercock P, et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 2004; 364:1321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edwards P, Arango M, Balica L, et al. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet 2005; 365:1957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMillan TM, Teasdale GM, Weir CJ, Stewart E. Death after head injury: the 13 year outcome of a case control study. J Neurol Neurosurg Psychiatry 2011; 82:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andelic N, Hammergren N, Bautz-Holter E, et al. Functional outcome and health-related quality of life 10 years after moderate-to-severe traumatic brain injury. Acta Neurol Scand 2009; 120:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoofien D, Gilboa A, Vakil E, Donovick PJ. Traumatic brain injury (TBI) 10-20 years later: a comprehensive outcome study of psychiatric symptomatology, cognitive abilities and psychosocial functioning. Brain Inj 2001; 15:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz DI, Polyak M, Coughlan D, et al. Natural history of recovery from brain injury after prolonged disorders of consciousness: outcome of patients admitted to inpatient rehabilitation with 1-4 year follow-up. Prog Brain Res 2009; 177:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaufmann MA, Buchmann B, Scheidegger D, et al. Severe head injury: should expected outcome influence resuscitation and first-day decisions? Resuscitation 1992; 23:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masel BE, DeWitt DS. Traumatic brain injury: a disease process, not an event. J Neurotrauma 2010; 27:1529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCredie VA, Alali AS, Xiong W, et al. Timing of withdrawal of life-sustaining therapies in severe traumatic brain injury: Impact on overall mortality. J Trauma Acute Care Surg 2016; 80:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sbordone RJ, Liter JC, Pettler-Jennings P. Recovery of function following severe traumatic brain injury: a retrospective 10-year follow-up. Brain Inj 1995; 9:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selassie AW, Zaloshnja E, Langlois JA, et al. Incidence of long-term disability following traumatic brain injury hospitalization, United States, 2003. J Head Trauma Rehabil 2008; 23:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomsen IV. Late psychosocial outcome in severe traumatic brain injury. Preliminary results of a third follow-up study after 20 years. Scand J Rehabil Med Suppl 1992; 26:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho KM, Honeybul S, Litton E. Delayed neurological recovery after decompressive craniectomy for severe nonpenetrating traumatic brain injury. Crit Care Med 2011; 39:2495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosner MJ, Rosner SD, Johnson AH. Cerebral perfusion pressure: management protocol and clinical results. J Neurosurg 1995; 83:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang JY, Gao GY, Li WP, et al. Early indicators of prognosis in 846 cases of severe traumatic brain injury. J Neurotrauma 2002; 19:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levin HS, Saydjari C, Eisenberg HM, et al. Vegetative state after closed-head injury. A Traumatic Coma Data Bank Report. Arch Neurol 1991; 48:580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu W, Jiang G, Chen Y, et al. Prediction of minimally conscious state with somatosensory evoked potentials in long-term unconscious patients after traumatic brain injury. J Trauma Acute Care Surg 2012; 72:1024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giacino JT, Whyte J, Bagiella E, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med 2012; 366:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andriessen TM, Horn J, Franschman G, et al. Epidemiology, severity classification, and outcome of moderate and severe traumatic brain injury: a prospective multicenter study. J Neurotrauma 2011; 28:2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watanitanon A, Lyons VH, Lele AV, et al. Clinical Epidemiology of Adults With Moderate Traumatic Brain Injury. Crit Care Med 2018; 46:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fabbri A, Servadei F, Marchesini G, et al. Early predictors of unfavourable outcome in subjects with moderate head injury in the emergency department. J Neurol Neurosurg Psychiatry 2008; 79:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Einarsen CE, van der Naalt J, Jacobs B, et al. Moderate Traumatic Brain Injury: Clinical Characteristics and a Prognostic Model of 12-Month Outcome. World Neurosurg 2018; 114:e1199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider EB, Sur S, Raymont V, et al. Functional recovery after moderate/severe traumatic brain injury: a role for cognitive reserve? Neurology 2014; 82:1636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lingsma HF, Roozenbeek B, Steyerberg EW, et al. Early prognosis in traumatic brain injury: from prophecies to predictions. Lancet Neurol 2010; 9:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schnüriger B, Inaba K, Abdelsayed GA, et al. The impact of platelets on the progression of traumatic intracranial hemorrhage. J Trauma 2010; 68:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calvi MR, Beretta L, Dell'Acqua A, et al. Early prognosis after severe traumatic brain injury with minor or absent computed tomography scan lesions. J Trauma 2011; 70:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Timmons SD, Bee T, Webb S, et al. Using the abbreviated injury severity and Glasgow Coma Scale scores to predict 2-week mortality after traumatic brain injury. J Trauma 2011; 71:1172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lingsma H, Andriessen TM, Haitsema I, et al. Prognosis in moderate and severe traumatic brain injury: external validation of the IMPACT models and the role of extracranial injuries. J Trauma Acute Care Surg 2013; 74:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin TK, Tsai HC, Hsieh TC. The impact of traumatic subarachnoid hemorrhage on outcome: a study with grouping of traumatic subarachnoid hemorrhage and transcranial Doppler sonography. J Trauma Acute Care Surg 2012; 73:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okasha AS, Fayed AM, Saleh AS. The FOUR score predicts mortality, endotracheal intubation and ICU length of stay after traumatic brain injury. Neurocrit Care 2014; 21:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henninger N, Izzy S, Carandang R, et al. Severe leukoaraiosis portends a poor outcome after traumatic brain injury. Neurocrit Care 2014; 21:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNett M, Amato S, Gianakis A, et al. The FOUR score and GCS as predictors of outcome after traumatic brain injury. Neurocrit Care 2014; 21:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skandsen T, Kvistad KA, Solheim O, et al. Prognostic value of magnetic resonance imaging in moderate and severe head injury: a prospective study of early MRI findings and one-year outcome. J Neurotrauma 2011; 28:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Firsching R, Woischneck D, Diedrich M, et al. Early magnetic resonance imaging of brainstem lesions after severe head injury. J Neurosurg 1998; 89:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lagares A, Ramos A, Pérez-Nuñez A, et al. The role of MR imaging in assessing prognosis after severe and moderate head injury. Acta Neurochir (Wien) 2009; 151:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moen KG, Brezova V, Skandsen T, et al. Traumatic axonal injury: the prognostic value of lesion load in corpus callosum, brain stem, and thalamus in different magnetic resonance imaging sequences. J Neurotrauma 2014; 31:1486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haghbayan H, Boutin A, Laflamme M, et al. The Prognostic Value of MRI in Moderate and Severe Traumatic Brain Injury: A Systematic Review and Meta-Analysis. Crit Care Med 2017; 45:e1280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Izzy S, Mazwi NL, Martinez S, et al. Revisiting Grade 3 Diffuse Axonal Injury: Not All Brainstem Microbleeds are Prognostically Equal. Neurocrit Care 2017; 27:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edlow BL, Giacino JT, Hirschberg RE, et al. Unexpected recovery of function after severe traumatic brain injury: the limits of early neuroimaging-based outcome prediction. Neurocrit Care 2013; 19:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mondello S, Buki A, Italiano D, Jeromin A. α-Synuclein in CSF of patients with severe traumatic brain injury. Neurology 2013; 80:1662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mercier E, Boutin A, Lauzier F, et al. Predictive value of S-100β protein for prognosis in patients with moderate and severe traumatic brain injury: systematic review and meta-analysis. BMJ 2013; 346:f1757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chabok SY, Moghadam AD, Saneei Z, et al. Neuron-specific enolase and S100BB as outcome predictors in severe diffuse axonal injury. J Trauma Acute Care Surg 2012; 72:1654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roozenbeek B, Lingsma HF, Lecky FE, et al. Prediction of outcome after moderate and severe traumatic brain injury: external validation of the International Mission on Prognosis and Analysis of Clinical Trials (IMPACT) and Corticoid Randomisation After Significant Head injury (CRASH) prognostic models. Crit Care Med 2012; 40:1609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han J, King NK, Neilson SJ, et al. External validation of the CRASH and IMPACT prognostic models in severe traumatic brain injury. J Neurotrauma 2014; 31:1146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panczykowski DM, Puccio AM, Scruggs BJ, et al. Prospective independent validation of IMPACT modeling as a prognostic tool in severe traumatic brain injury. J Neurotrauma 2012; 29:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olivecrona M, Olivecrona Z. Use of the CRASH study prognosis calculator in patients with severe traumatic brain injury treated with an intracranial pressure-targeted therapy. J Clin Neurosci 2013; 20:996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olivecrona M, Koskinen LO. The IMPACT prognosis calculator used in patients with severe traumatic brain injury treated with an ICP-targeted therapy. Acta Neurochir (Wien) 2012; 154:1567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MRC CRASH Trial Collaborators, Perel P, Arango M, et al. Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients. BMJ 2008; 336:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steyerberg EW, Mushkudiani N, Perel P, et al. Predicting outcome after traumatic brain injury: development and international validation of prognostic scores based on admission characteristics. PLoS Med 2008; 5:e165; discussion e165.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4826 Version 34.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28301451" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Traumatic Brain Injury-Related Emergency Department Visits, Hospitalizations, and Deaths - United States, 2007 and 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28301451" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Traumatic Brain Injury-Related Emergency Department Visits, Hospitalizations, and Deaths - United States, 2007 and 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28301451" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Traumatic Brain Injury-Related Emergency Department Visits, Hospitalizations, and Deaths - United States, 2007 and 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4136544" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Assessment of coma and impaired consciousness. A practical scale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The Traumatic Coma Data Bank: design, methods, and baseline characteristics
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Definition of mild traumatic brain injury
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26927279" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Moderate Traumatic Brain Injury: The Grey Zone of Neurotrauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32804788" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Potentially Severe (Moderate) Traumatic Brain Injury: A New Categorization Proposal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11303182" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Minor head injury: 13 is an unlucky number.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19197220" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Patients with moderate head injury: a prospective multicenter study of 315 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17511535" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Guidelines for the management of severe traumatic brain injury. Introduction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9202767" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : EBIC-guidelines for management of severe head injury in adults. European Brain Injury Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10833574" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The management of acute neurotrauma in rural and remote locations: A set of guidelines for the care of head and spinal injuries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12847337" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 1: Introduction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27654000" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16257340" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Trends in head injury outcome from 1989 to 2003 and the effect of neurosurgical care: an observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15640647" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Length of stay and mortality in neurocritically ill patients: impact of a specialized neurocritical care team.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10669432" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Neurosurgical units working beyond safe capacity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15640630" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The impact of a neurointensivist-led team on a semiclosed neurosciences intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16753622" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Clinical and neuroimaging features of severely brain-injured patients treated in a neurosurgical unit compared with patients treated in peripheral non-neurosurgical hospitals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20699734" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Trauma center designation correlates with functional independence after severe but not moderate traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23271089" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : High-volume trauma centers have better outcomes treating traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23200264" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Effect of implementation of a paediatric neurocritical care programme on outcomes after severe traumatic brain injury: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17511549" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Guidelines for the management of severe traumatic brain injury. I. Blood pressure and oxygenation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17375993" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Prognostic value of secondary insults in traumatic brain injury: results from the IMPACT study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2496817" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Pulse oximetry at the roadside: a study of pulse oximetry in immediate care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8614077" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Hypoxemia and arterial hypotension at the accident scene in head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8459458" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The role of secondary brain injury in determining outcome from severe head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11585502" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Hypotension, hypoxia, and head injury: frequency, duration, and consequences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24206920" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The association between admission systolic blood pressure and mortality in significant traumatic brain injury: a multi-centre cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12186460" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Predicting recovery in patients suffering from traumatic brain injury by using admission variables and physiological data: a comparison between decision tree analysis and logistic regression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11940738" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Fluid thresholds and outcome from severe brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9197850" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Endotracheal intubation in the field improves survival in patients with severe head injury. Trauma Research and Education Foundation of San Diego.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12184855" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Outcome of traumatic brain injuries in 1,508 patients: impact of prehospital care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20699737" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Prehospital airway and ventilation management: a trauma score and injury severity score-based analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18203044" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Guidelines for prehospital management of traumatic brain injury 2nd edition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22841182" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Balancing the potential risks and benefits of out-of-hospital intubation in traumatic brain injury: the intubation/hyperventilation effect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19648153" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Pre-hospital tracheal intubation in patients with traumatic brain injury: systematic review of current evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15920406" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The impact of prehospital endotracheal intubation on outcome in moderate to severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16046940" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The impact of aeromedical response to patients with moderate to severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21107105" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Prehospital rapid sequence intubation improves functional outcome for patients with severe traumatic brain injury: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15026402" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Prehospital hypertonic saline resuscitation of patients with hypotension and severe traumatic brain injury: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20924011" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Out-of-hospital hypertonic resuscitation following severe traumatic brain injury: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32897344" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16178024" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Validation of a new coma scale: The FOUR score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27224686" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A Comparative Study of Glasgow Coma Scale and Full Outline of Unresponsiveness Scores for Predicting Long-Term Outcome After Brain Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27001246" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A comparison of the Full Outline of UnResponsiveness (FOUR) score and Glasgow Coma Score (GCS) in predictive modelling in traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28913634" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Emergency Neurological Life Support: Intracranial Hypertension and Herniation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31623894" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21724564" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24267513" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Tranexamic acid for patients with traumatic brain injury: a randomized, double-blinded, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25447601" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Tranexamic acid for traumatic brain injury: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16710967" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Surgical management of acute epidural hematomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16710968" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Surgical management of acute subdural hematomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16540745" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Surgical management of posterior fossa mass lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16540746" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Surgical management of traumatic parenchymal lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11505195" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Surgical management of penetrating brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11505198" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Antibiotic prophylaxis for penetrating brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16540744" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Surgical management of depressed cranial fractures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12634529" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Patients with a head injury who "talk and die" in the 1990s.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/51187" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Patients with head injury who talk and die.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10626937" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The value of the "worst" computed tomographic scan in clinical studies of moderate and severe head injury. European Brain Injury Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16575328" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Acute traumatic intraparenchymal hemorrhage: risk factors for progression in the early post-injury period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11794591" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Progressive hemorrhage after head trauma: predictors and consequences of the evolving injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18491950" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Progression of traumatic intracerebral hemorrhage: a prospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20421059" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Scheduled repeat CT scanning for traumatic brain injury remains important in assessing head injury progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22112983" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Do routinely repeated computed tomography scans in traumatic brain injury influence management? A prospective observational study in a level 1 trauma center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15128116" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Routinely repeated computed tomography after blunt head trauma: does it benefit patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17563645" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Indications for routine repeat head computed tomography (CT) stratified by severity of traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22182869" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Early parenchymal contrast extravasation predicts subsequent hemorrhage progression, clinical deterioration, and need for surgery in patients with traumatic cerebral contusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17761591" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Saline or albumin for fluid resuscitation in patients with traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29485925" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Balanced Crystalloids versus Saline in Critically Ill Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1588625" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Cerebral blood flow, cerebral blood volume, and cerebrovascular reactivity after severe head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1607958" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Blood pressure and intracranial pressure-volume dynamics in severe head injury: relationship with cerebral blood flow.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2738644" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Cerebral blood flow and metabolism in severely head-injured children. Part 2: Autoregulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10616075" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Intracranial hypertension and cerebral perfusion pressure: influence on neurological deterioration and outcome in severe head injury. The Executive Committee of the International Selfotel Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2117669" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Cerebral perfusion pressure management in head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10548187" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Prevention of secondary ischemic insults after severe head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15739560" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Pressure reactivity as a guide in the treatment of cerebral perfusion pressure in patients with brain trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11596949" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Adult respiratory distress syndrome: a complication of induced hypertension after severe head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16896859" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : The "Lund Concept" for the treatment of severe head trauma--physiological principles and clinical application.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21841511" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Intubation patterns and outcomes in patients with computed tomography-verified traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10616076" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : No reduction in cerebral metabolism as a result of early moderate hyperventilation following severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15888864" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Hyperventilation in head injury: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11794610" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Cerebral tissue PO2 and SjvO2 changes during moderate hyperventilation in patients with severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12352026" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Effect of hyperventilation on cerebral blood flow in traumatic head injury: clinical relevance and monitoring correlates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12483048" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Effect of hyperventilation on extracellular concentrations of glutamate, lactate, pyruvate, and local cerebral blood flow in patients with severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1919695" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Adverse effects of prolonged hyperventilation in patients with severe head injury: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17511553" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Guidelines for the management of severe traumatic brain injury. XIV. Hyperventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27848125" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : The Effect of Positive End-Expiratory Pressure on Intracranial Pressure and Cerebral Hemodynamics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16215394" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Effects of positive end-expiratory pressure on regional cerebral blood flow, intracranial pressure, and brain tissue oxygenation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26307004" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Effects of positive end-expiratory pressure on brain tissue oxygen pressure of severe traumatic brain injury patients with acute respiratory distress syndrome: A pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27651443" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Changes in Therapeutic Intensity Level Following Airway Pressure Release Ventilation in Severe Traumatic Brain Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2115976" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11687070" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Anti-epileptic drugs for preventing seizures following acute traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19898966" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14511390" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Risk factors for posttraumatic seizures in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14511389" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Epidemiology of posttraumatic epilepsy: a critical review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10541231" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Increased incidence and impact of nonconvulsive and convulsive seizures after traumatic brain injury as detected by continuous electroencephalographic monitoring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16774627" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Continuous EEG monitoring in patients with traumatic brain injury reveals a high incidence of epileptiform activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27637399" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Seizures and the Role of Anticonvulsants After Traumatic Brain Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15662039" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23425733" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27295203" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : The safety and efficacy of levetiracetam versus phenytoin for seizure prophylaxis after traumatic brain injury: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17511543" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Guidelines for the management of severe traumatic brain injury. V. Deep vein thrombosis prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19430251" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Traumatic brain injury is associated with the development of deep vein thrombosis independent of pharmacological prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19001969" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Early venous thromboembolism prophylaxis with enoxaparin in patients with blunt traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12049541" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Prospective evaluation of the safety of enoxaparin prophylaxis for venous thromboembolism in patients with intracranial hemorrhagic injuries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21217476" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Interrupted pharmocologic thromboprophylaxis increases venous thromboembolism in traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21307729" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Is early venous thromboembolism prophylaxis safe in trauma patients with intracranial hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21459632" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Safety and efficacy of prophylactic anticoagulation in patients with traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22846950" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Chemical venous thromboembolic prophylaxis is safe and effective for patients with traumatic brain injury when started 24 hours after the absence of hemorrhage progression on head CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22929493" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Is low-molecular-weight heparin safe for venous thromboembolism prophylaxis in patients with traumatic brain injury? A Western Trauma Association multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22914079" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : A randomized, double-blinded, placebo-controlled pilot trial of anticoagulation in low-risk traumatic brain injury: The Delayed Versus Early Enoxaparin Prophylaxis I (DEEP I) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29895339" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : A Systematic Review of the Risks and Benefits of Venous Thromboembolism Prophylaxis in Traumatic Brain Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18166989" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Coagulation disorders after traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19901655" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Abnormal coagulation tests are associated with progression of traumatic intracranial hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19806475" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Acute coagulopathy in isolated blunt traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1545882" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Delayed brain injury after head trauma: significance of coagulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17375997" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Multivariable prognostic analysis in traumatic brain injury: results from the IMPACT study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25052157" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Traumatic brain injury associated coagulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17706857" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : The association of coagulopathy and traumatic brain injury in patients with isolated head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25494436" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Traumatic brain injury is not associated with coagulopathy out of proportion to injury in other body regions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25159244" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : The significance of platelet count in traumatic brain injury patients on antiplatelet therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22695437" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Utility of platelet transfusion in adult patients with traumatic intracranial hemorrhage and preinjury antiplatelet use: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20091656" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Haemostatic drugs for traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18496183" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10690722" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : The influence of hyperglycemia on neurological outcome in patients with severe head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15674149" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : The impact of hyperglycemia on patients with severe brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1885972" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Hyperglycemia and neurological outcome in patients with head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18936695" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Impact of tight glycemic control on cerebral glucose metabolism after severe brain injury: a microdialysis study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19337864" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Induced normothermia attenuates intracranial hypertension and reduces fever burden after severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19821062" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Effect of shivering on brain tissue oxygenation during induced normothermia in patients with severe brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21537207" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : The impact of nontherapeutic hypothermia on outcomes after severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20495781" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Gastric versus transpyloric feeding in severe traumatic brain injury: a prospective, randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20027012" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Retrospective analysis of the risk factors and pathogens associated with early-onset ventilator-associated pneumonia in surgical-ICU head-trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18590432" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Effect of early nutrition on deaths due to severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21965459" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Effect of early compared with delayed enteral nutrition on endocrine function in patients with traumatic brain injury: an open-labeled randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Impact of ICP instability and hypotension on outcome in patients with severe head trauma
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11888450" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Determinants of mortality in patients with severe blunt head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23011528" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Mortality and long-term functional outcome associated with intracranial pressure after traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10834711" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Long-term outcome after medical reversal of transtentorial herniation in patients with supratentorial mass lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18272864" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Reversal of transtentorial herniation with hypertonic saline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34173156" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Safety and Efficacy of 23.4% Sodium Chloride Administered via Peripheral Venous Access for the Treatment of Cerebral Herniation and Intracranial Pressure Elevation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17511544" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Guidelines for the management of severe traumatic brain injury. VI. Indications for intracranial pressure monitoring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23234472" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : A trial of intracranial-pressure monitoring in traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26414629" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : A Propensity Score Analysis of the Impact of Invasive Intracranial Pressure Monitoring on Outcomes after Severe Traumatic Brain Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14652432" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Intracranial pressure monitoring in a resource-constrained environment: a technical note.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21964774" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Critical thresholds for cerebrovascular reactivity after traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5832775" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Continuous recording of the ventricular-fluid pressure in patients with severe acute traumatic brain injury. A preliminary report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17511539" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Guidelines for the management of severe traumatic brain injury. II. Hyperosmolar therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22488001" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Factors influencing intracranial pressure monitoring guideline compliance and outcome after severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22900846" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Increased mortality in patients with severe traumatic brain injury treated without intracranial pressure monitoring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28480113" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Noninvasive monitoring intracranial pressure - A review of available modalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17175372" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Transorbital sonographic monitoring of optic nerve diameter in patients with severe brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21769456" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Optic nerve ultrasound for the detection of raised intracranial pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30019201" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Optic nerve sheath diameter measured sonographically as non-invasive estimator of intracranial pressure: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33048902" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : A Prospective Study of Optic Nerve Ultrasound for the Detection of Elevated Intracranial Pressure in Severe Traumatic Brain Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26940914" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Non-invasive Monitoring of Intracranial Pressure Using Transcranial Doppler Ultrasonography: Is It Possible?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28241847" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : The accuracy of transcranial Doppler in excluding intracranial hypertension following acute brain injury: a multicenter prospective pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28742869" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Ultrasound non-invasive measurement of intracranial pressure in neurointensive care: A prospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23943318" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Intermittent versus continuous cerebrospinal fluid drainage management in adult severe traumatic brain injury: assessment of intracranial pressure burden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30113379" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28913751" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Emergency Neurological Life Support: Airway, Ventilation, and Sedation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19644774" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Effects of the neurological wake-up test on intracranial pressure and cerebral perfusion pressure in brain-injured patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10350250" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Propofol in the treatment of moderate and severe head injury: a randomized, prospective double-blinded pilot trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19397790" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Propofol: neuroprotection in an in vitro model of traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19051063" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Vasopressors and propofol infusion syndrome in severe head trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21436162" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Hypertonic saline and mannitol therapy in critical care neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26673517" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Mannitol or hypertonic saline in the setting of traumatic brain injury: What have we learned?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26673517" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Mannitol or hypertonic saline in the setting of traumatic brain injury: What have we learned?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15644669" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Randomized, controlled trial on the effect of a 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12794404" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Isovolume hypertonic solutes (sodium chloride or mannitol) in the treatment of refractory posttraumatic intracranial hypertension: 2 mL/kg 7.5% saline is more effective than 2 mL/kg 20% mannitol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28712906" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : A Comparison of Pharmacologic Therapeutic Agents Used for the Reduction of Intracranial Pressure After Traumatic Brain Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26988719" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Hypertonic saline in severe traumatic brain injury: a systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26825644" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : A Systematic Review of Randomized Controlled Trials Comparing Hypertonic Sodium Solutions and Mannitol for Traumatic Brain Injury: Implications for Emergency Department Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25380107" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Hypertonic saline reduces cumulative and daily intracranial pressure burdens after severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21787184" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25929908" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Comparison of equimolar doses of mannitol and hypertonic saline for the treatment of elevated intracranial pressure after traumatic brain injury: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19293171" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Effect of mannitol and hypertonic saline on cerebral oxygenation in patients with severe traumatic brain injury and refractory intracranial hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21087203" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Comparison of mannitol and hypertonic saline in the treatment of severe brain injuries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9464749" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Hypertonic saline resuscitation of patients with head injury: a prospective, randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16239885" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Effects of 23.4% sodium chloride solution in reducing intracranial pressure in patients with traumatic brain injury: a preliminary study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29140948" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : Hypertonic saline resuscitation after emergent laparotomy and temporary abdominal closure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6768226" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : Methodology for the control of intracranial pressure with hypertonic mannitol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6413884" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : Effect of mannitol on increased intracranial pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6413661" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : Mannitol causes compensatory cerebral vasoconstriction and vasodilation in response to blood viscosity changes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17297315" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : Effects of mannitol bolus administration on intracranial pressure, cerebral extracellular metabolites, and tissue oxygenation in severely head-injured patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22913684" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : Hyperosmolar therapy for raised intracranial pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18447720" id="rid189" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          190 : Neurosurgical implications of mannitol accumulation within a meningioma and its peritumoral region demonstrated by magnetic resonance spectroscopy: case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17019386" id="rid190" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          191 : Passage of mannitol into the brain around gliomas: a potential cause of rebound phenomenon. A study on 21 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24196399" id="rid191" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          192 : Hypernatremia in patients with severe traumatic brain injury: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32761068" id="rid192" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          193 : Guidelines for the Management of Severe Traumatic Brain Injury: 2020 Update of the Decompressive Craniectomy Recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23752906" id="rid193" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          194 : Decompressive craniectomy: past, present and future.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28806209" id="rid194" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          195 : Refractory Intracranial Hypertension: The Role of Decompressive Craniectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19930556" id="rid195" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          196 : Effects of unilateral decompressive craniectomy on patients with unilateral acute post-traumatic brain swelling after severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15941372" id="rid196" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          197 : Efficacy of standard trauma craniectomy for refractory intracranial hypertension with severe traumatic brain injury: a multicenter, prospective, randomized controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21434843" id="rid197" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          198 : Decompressive craniectomy in diffuse traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21434844" id="rid198" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          199 : Clinical value of decompressive craniectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27602507" id="rid199" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          200 : Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23235573" id="rid200" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          201 : Barbiturates for acute traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17511550" id="rid201" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          202 : Guidelines for the management of severe traumatic brain injury. XI. Anesthetics, analgesics, and sedatives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26203702" id="rid202" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          203 : Ventilator-Associated Pneumonia in Pediatric Traumatic Brain Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29472424" id="rid203" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          204 : Pentobarbital-induced lactic acidosis following status epilepticus barbiturate coma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18698010" id="rid204" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          205 : Propylene glycol-induced lactic acidosis in a patient receiving continuous infusion pentobarbital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11207351" id="rid205" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          206 : Lack of effect of induction of hypothermia after acute brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22448655" id="rid206" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          207 : Therapeutic hypothermia for the management of intracranial hypertension in severe traumatic brain injury: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17511540" id="rid207" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          208 : Guidelines for the management of severe traumatic brain injury. III. Prophylactic hypothermia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19271965" id="rid208" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          209 : Hypothermia following pediatric traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19160187" id="rid209" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          210 : Hypothermia for traumatic head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28933514" id="rid210" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          211 : Hypothermia for traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12799408" id="rid211" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          212 : Prolonged therapeutic hypothermia after traumatic brain injury in adults: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12915937" id="rid212" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          213 : Hypothermia in the management of traumatic brain injury. A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12117354" id="rid213" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          214 : The role of hypothermia in the management of severe brain injury: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23353036" id="rid214" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          215 : Role of therapeutic hypothermia in improving outcome after traumatic brain injury: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21169065" id="rid215" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          216 : Very early hypothermia induction in patients with severe brain injury (the National Acute Brain Injury Study: Hypothermia II): a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26444221" id="rid216" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          217 : Hypothermia for Intracranial Hypertension after Traumatic Brain Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18525042" id="rid217" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          218 : Hypothermia therapy after traumatic brain injury in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23664370" id="rid218" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          219 : Comparison of hypothermia and normothermia after severe traumatic brain injury in children (Cool Kids): a phase 3, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9468174" id="rid219" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          220 : The first decade of continuous monitoring of jugular bulb oxyhemoglobinsaturation: management strategies and clinical outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12067878" id="rid220" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          221 : Continuous jugular venous oximetry in the neurointensive care unit--a brief review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8006653" id="rid221" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          222 : Jugular venous desaturation and outcome after head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19384213" id="rid222" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          223 : Brain tissue oxygen and outcome after severe traumatic brain injury: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17511548" id="rid223" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          224 : Guidelines for the management of severe traumatic brain injury. X. Brain oxygen monitoring and thresholds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20415526" id="rid224" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          225 : Brain tissue oxygen-directed management and outcome in patients with severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19463048" id="rid225" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          226 : Brain tissue oxygen monitoring in traumatic brain injury and major trauma: outcome analysis of a brain tissue oxygen-directed therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29028696" id="rid226" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          227 : Brain Oxygen Optimization in Severe Traumatic Brain Injury Phase-II: A Phase II Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19578321" id="rid227" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          228 : Microdialysis: is it ready for prime time?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24072457" id="rid228" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          229 : Cerebral microdialysis in traumatic brain injury and subarachnoid hemorrhage: state of the art.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18828700" id="rid229" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          230 : Continuous monitoring of cerebrovascular pressure reactivity in patients with head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24506248" id="rid230" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          231 : Patient-specific thresholds of intracranial pressure in severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18635021" id="rid231" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          232 : Moderate and severe traumatic brain injury in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25493978" id="rid232" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          233 : A clinical trial of progesterone for severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25493974" id="rid233" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          234 : Very early administration of progesterone for acute traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23168823" id="rid234" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          235 : Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25058216" id="rid235" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          236 : Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26452709" id="rid236" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          237 : Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18843689" id="rid237" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          238 : Magnesium for acute traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23235612" id="rid238" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          239 : Hyperbaric oxygen therapy for the adjunctive treatment of traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19621985" id="rid239" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          240 : Safety and tolerability of cyclosporin a in severe traumatic brain injury patients: results from a prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19249984" id="rid240" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          241 : Emerging treatments for traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15474134" id="rid241" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          242 : Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15936423" id="rid242" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          243 : Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21282727" id="rid243" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          244 : Death after head injury: the 13 year outcome of a case control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18976326" id="rid244" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          245 : Functional outcome and health-related quality of life 10 years after moderate-to-severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11260769" id="rid245" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          246 : Traumatic brain injury (TBI) 10-20 years later: a comprehensive outcome study of psychiatric symptomatology, cognitive abilities and psychosocial functioning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19818896" id="rid246" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          247 : Natural history of recovery from brain injury after prolonged disorders of consciousness: outcome of patients admitted to inpatient rehabilitation with 1-4 year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1321479" id="rid247" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          248 : Severe head injury: should expected outcome influence resuscitation and first-day decisions?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20504161" id="rid248" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          249 : Traumatic brain injury: a disease process, not an event.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26595711" id="rid249" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          250 : Timing of withdrawal of life-sustaining therapies in severe traumatic brain injury: Impact on overall mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7541681" id="rid250" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          251 : Recovery of function following severe traumatic brain injury: a retrospective 10-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18362766" id="rid251" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          252 : Incidence of long-term disability following traumatic brain injury hospitalization, United States, 2003.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1488637" id="rid252" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          253 : Late psychosocial outcome in severe traumatic brain injury. Preliminary results of a third follow-up study after 20 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21705893" id="rid253" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          254 : Delayed neurological recovery after decompressive craniectomy for severe nonpenetrating traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7490638" id="rid254" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          255 : Cerebral perfusion pressure: management protocol and clinical results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12184856" id="rid255" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          256 : Early indicators of prognosis in 846 cases of severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2039378" id="rid256" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          257 : Vegetative state after closed-head injury. A Traumatic Coma Data Bank Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22491621" id="rid257" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          258 : Prediction of minimally conscious state with somatosensory evoked potentials in long-term unconscious patients after traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22375973" id="rid258" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          259 : Placebo-controlled trial of amantadine for severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21787177" id="rid259" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          260 : Epidemiology, severity classification, and outcome of moderate and severe traumatic brain injury: a prospective multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29369057" id="rid260" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          261 : Clinical Epidemiology of Adults With Moderate Traumatic Brain Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17766433" id="rid261" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          262 : Early predictors of unfavourable outcome in subjects with moderate head injury in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29614364" id="rid262" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          263 : Moderate Traumatic Brain Injury: Clinical Characteristics and a Prognostic Model of 12-Month Outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24759845" id="rid263" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          264 : Functional recovery after moderate/severe traumatic brain injury: a role for cognitive reserve?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20398861" id="rid264" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          265 : Early prognosis in traumatic brain injury: from prophecies to predictions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20386283" id="rid265" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          266 : The impact of platelets on the progression of traumatic intracranial hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21307746" id="rid266" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          267 : Early prognosis after severe traumatic brain injury with minor or absent computed tomography scan lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22071922" id="rid267" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          268 : Using the abbreviated injury severity and Glasgow Coma Scale scores to predict 2-week mortality after traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23354263" id="rid268" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          269 : Prognosis in moderate and severe traumatic brain injury: external validation of the IMPACT models and the role of extracranial injuries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22743382" id="rid269" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          270 : The impact of traumatic subarachnoid hemorrhage on outcome: a study with grouping of traumatic subarachnoid hemorrhage and transcranial Doppler sonography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24865273" id="rid270" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          271 : The FOUR score predicts mortality, endotracheal intubation and ICU length of stay after traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24752459" id="rid271" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          272 : Severe leukoaraiosis portends a poor outcome after traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24408147" id="rid272" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          273 : The FOUR score and GCS as predictors of outcome after traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21401308" id="rid273" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          274 : Prognostic value of magnetic resonance imaging in moderate and severe head injury: a prospective study of early MRI findings and one-year outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9817405" id="rid274" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          275 : Early magnetic resonance imaging of brainstem lesions after severe head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19224121" id="rid275" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          276 : The role of MR imaging in assessing prognosis after severe and moderate head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24773587" id="rid276" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          277 : Traumatic axonal injury: the prognostic value of lesion load in corpus callosum, brain stem, and thalamus in different magnetic resonance imaging sequences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29028764" id="rid277" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          278 : The Prognostic Value of MRI in Moderate and Severe Traumatic Brain Injury: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28477152" id="rid278" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          279 : Revisiting Grade 3 Diffuse Axonal Injury: Not All Brainstem Microbleeds are Prognostically Equal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23860665" id="rid279" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          280 : Unexpected recovery of function after severe traumatic brain injury: the limits of early neuroimaging-based outcome prediction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23553480" id="rid280" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          281 : α-Synuclein in CSF of patients with severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23558282" id="rid281" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          282 : Predictive value of S-100βprotein for prognosis in patients with moderate and severe traumatic brain injury: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22695436" id="rid282" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          283 : Neuron-specific enolase and S100BB as outcome predictors in severe diffuse axonal injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22511138" id="rid283" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          284 : Prediction of outcome after moderate and severe traumatic brain injury: external validation of the International Mission on Prognosis and Analysis of Clinical Trials (IMPACT) and Corticoid Randomisation After Significant Head injury (CRASH) prognostic models.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24568201" id="rid284" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          285 : External validation of the CRASH and IMPACT prognostic models in severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21933014" id="rid285" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          286 : Prospective independent validation of IMPACT modeling as a prognostic tool in severe traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23702375" id="rid286" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          287 : Use of the CRASH study prognosis calculator in patients with severe traumatic brain injury treated with an intracranial pressure-targeted therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22543506" id="rid287" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          288 : The IMPACT prognosis calculator used in patients with severe traumatic brain injury treated with an ICP-targeted therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18270239" id="rid288" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          289 : Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18684008" id="rid289" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          290 : Predicting outcome after traumatic brain injury: development and international validation of prognostic scores based on admission characteristics.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
